I. INTRODUCTION TO Ca 2؉ SIGNALING
In the course of evolution, a number of agents have emerged as carriers of signals that are essential for the correct functioning of cell life. Ca 2ϩ is the most versatile: other messengers are normally committed to the regulation of a single cell function, or at most a few of them. Ca 2ϩ instead regulates a very large list of essential functions, beginning with the origin of new cell life at fertilization and ending with its termination in the process of programmed cell death. Between these two events, Ca 2ϩ transmits signals to functions as fundamental as gene transcription, muscle contraction (and motility in general), secretion (including that of neurotransmitters), and generation of fuels in various metabolic pathways (39) .
The involvement of Ca 2ϩ in so many fundamental cell processes naturally demands its efficient and precise control. The task is performed by specialized proteins that bind Ca 2ϩ with great specificity and affinity in the intracellular ambient, in which in most cases free Ca 2ϩ oscillates around 100 nM. These proteins belong to two broad classes: those that are intrinsic to membranes and move Ca 2ϩ across them, thus acting solely as Ca 2ϩ buffers, and those that are not membrane-bound but, in addition to buffering Ca 2ϩ , also decode the message it carries for the benefit of protein (enzyme) targets. These proteins are thus also appropriately called Ca 2ϩ sensors. The discovery of Ca 2ϩ sensor proteins can be traced back to the pioneering work by Ebashi et al. (79) on troponin, whose C-subunit is the Ca 2ϩ receptor in the muscle molecule. Troponin C is the progenitor of the family of proteins that have later been defined as EF-hand proteins. The family has now grown to contain over 600 members (208) . The fine details of the process by which Ca 2ϩ sensors decode the Ca 2ϩ signal have so far only been clarified at the atomic level for very few proteins, among which calmodulin is probably the most important. Essentially on the basis of the work on calmodulin, and on a few other Ca 2ϩ sensor proteins, it is generally assumed that the essence of the signal-decoding process is the conformational change of the sensor protein upon binding Ca 2ϩ and upon contacting the target enzymes.
The processing of the Ca 2ϩ message by specialized proteins indicates that, as a rule, Ca 2ϩ does not transduce signals per se: the intermediation of a sensor protein that binds it and then contacts the targets of the message appears essential. Even if this is indeed so in most cases, a minority of proteins, enzymes or otherwise, may bind Ca 2ϩ to sites in their own structure and decode its signal directly, without the intermediation of external sensor proteins: as an important example, one could quote protein kinase C (216) , which is thus for all purposes a bona fide Ca 2ϩ sensor enzyme itself. In still other cases, Ca 2ϩ -regulated enzymes contain not only the calmodulin binding domains that accept the Ca 2ϩ message after it has been processed by calmodulin, but also a separate calmodulin-like subunit. This is, for instance, the case of calcineurin (6) , an enzyme which is thus under dual Ca 2ϩ
regulation. An even more complex case is that of calpain, which contains a covalently bound calmodulin-like structure that binds Ca 2ϩ within the catalytic subunit, but also a separate calmodulin-like, smaller subunit (20) .
The decoding of the Ca 2ϩ message demands that its spatiotemporal distribution in the environment of the sensor proteins be very carefully modulated. This is made possible by the operation of membrane-intrinsic Ca 2ϩ -protein transporters and channels that move Ca 2ϩ back and forth across membrane boundaries, satisfying the demands of the decoding proteins and, in turn, of the targets of the Ca 2ϩ -signaling function. These membrane intrinsic proteins belong to several subclasses that vary in transport mechanism, affinity for Ca 2ϩ , and total transport capacity. The ATPases are high-affinity, low-capacity systems; the exchangers (mostly Na ϩ /Ca 2ϩ exchangers) have opposite properties, whereas the channels are proteinaceous structures that let Ca 2ϩ flow passively across membranes when a number of gating mechanisms induce their opening (43) . Voltage-gated (47) and ligand-gated (281) channels have been known and studied for a long time. Trp channels (309) and store-operated channels (234) have joined the field later, but recent important advances have raised interest in them. Lastly, an electrophoretic uniporter mediates the charge-uncompensated entry of Ca 2ϩ into mitochondria in response to the negative-inside membrane potential generated by the asymmetric topography and operation of the respiratory chain components (157) .
The generation, processing, and control of the Ca 2ϩ signal now define a large area of cell biochemistry and physiology. This review will not discuss it in detail, as its emphasis will primarily be on Ca 2ϩ pumps and the role of their dysfunctions in the disturbance of the Ca 2ϩ signal. In addition to those quoted in the paragraphs above, a number of other reviews deal in appropriate detail with other important aspects of the Ca 2ϩ signaling field: for instance, the matter of the Ca 2ϩ microdomains in cells (251) and of the generation of polarized Ca 2ϩ signals (238) . They could be consulted to complement the information offered in this succinct preamble (19, 39, 43) . In the next section, this contribution will only discuss in some detail the aspects of the Ca 2ϩ signaling area that are especially relevant to its focus.
II. SOME SPECIAL PROPERTIES OF THE
Ca 2؉ SIGNAL
A. Autoregulation
In addition to versatility, the Ca 2ϩ signal has a number of other distinctive properties. Some have been comprehensively discussed elsewhere (40) ; thus it will only be necessary to discuss here the two that are especially relevant to the topic of this article. One is the autoregulatory nature of the signal, which occurs both at the transcriptional and posttranscriptional levels: autoregulation means that the expression and the activity of a number of proteins that control Ca 2ϩ in cells are regulated by the Ca 2ϩ signal itself. That Ca 2ϩ regulates the transcription of a number of genes has long been known (259) . Both early and late response genes may be controlled by Ca 2ϩ : a significant portion of the information now available on the topic has been generated by the work on CREB, a transcription factor of the bZIP family that binds to the cAMP responsive element (CRE) and to the Ca 2ϩ responsive element (CARE) on DNA and becomes phosphorylated and activated by calmodulin kinases. The Ca 2ϩ -dependent phosphatase calcineurin then regulates the phosphorylation state of CREB in a complex process also involving other protein phosphatases. Other aspects of the regulation of genes by Ca 2ϩ are of general interest, but in the context of this review, it will only be necessary to discuss briefly the regulation of genes involved in the control of Ca 2ϩ . This autoregulation has been studied most extensively in neurons. A series of studies on cultured cerebellar granular cells have shown that the longterm survival of the cells depends on a modest increase of cytosolic Ca 2ϩ , which in the cultures is achieved by the partial opening of L-type Ca 2ϩ channels (42) . Even if modest, the increase nevertheless demands a dramatic rearrangement of the pattern of expression of a number of plasma membrane Ca 2ϩ transporters and of intracellular Ca 2ϩ channels. Under the culturing conditions that prolong the survival of the granules, two of the four basic isoforms of the plasma membrane Ca 2ϩ pump (PMCA, see below) become slowly upregulated, whereas another PMCA isoform (PMCA4) disappears instead rapidly. The expression of still another PMCA isoform (PMCA1) remains quantitatively constant, but an alternative splicing switch occurs that privileges a COOH-terminally truncated, probably less active variant. The rearrangement of the pattern of expression also affects the plasma membrane Na ϩ /Ca 2ϩ exchanger (NCX): one isoform (NCX3) is slowly upregulated, while another (NCX2) disappears very rapidly. The intracellular inositol 1,4,5-trisphosphate (InsP 3 )-gated Ca 2ϩ channel also becomes slowly upregulated. The autoregulatory character of this complex transcriptional rearrangement is further emphasized by the finding that the downregulation of PMCA4 and NCX2, as well as the upregulation of the InsP 3 receptor, as was the case for CREB, are mediated by calcineurin, the protein phosphatase which is itself the target of dual regulation by Ca 2ϩ (see above). At a first glance, it may seem surprising that such a modest increase of the set-point of cytosolic Ca 2ϩ should demand a complete reprogramming of the expression of Ca 2ϩ transporters. But the finding underlines the importance of controlling Ca 2ϩ with utmost precision: to promote the survival of the granule cells and, possibly, to fulfill the spatial and temporal Ca 2ϩ signaling requirements of mature, as opposed to immature cells, Ca 2ϩ should evidently increase, but only to a new modestly elevated set point, and no more. To reach this goal, for reasons which we still do not fully understand, several membrane transporters, not just one, must be reprogrammed. Ca 2ϩ can also influence gene transcription without the intermediation of protein kinases and phosphatases, i.e., by interacting directly with transcription factors. A very interesting example of this type of transcriptional regulation is that mediated by the downstream regulatory element antagonistic modulator (DREAM), a Ca 2ϩ -binding protein that acts as a gene repressor (45) . In the Ca 2ϩ -free form, it represses transcription by binding to specific DNA sites in the promoters of several genes. The binding of Ca 2ϩ removes DREAM from the sites, restoring transcription. From the autoregulation angle, it is interesting that one of the genes controlled by DREAM in this way is that for NCX3, a plasma membrane Na/Ca exchanger isoform that is particularly important to Ca 2ϩ homeostasis in neurons (103) . This is not the only example of DREAM-mediated autoregulation of the Ca 2ϩ signal, as another Ca 2ϩ -related gene controlled by DREAM is that for the L-type Ca 2ϩ channel, which is the most important entry path for Ca 2ϩ in heart and other excitable cells (71) .
Autoregulation of the Ca 2ϩ signal also occurs at the posttranscriptional level, the best known case being perhaps that of the PMCAs. They are all activated by Ca 2ϩ -calmodulin (141) , which interacts with a specific domain in their COOH-terminal cytosolic tail (see below). A calmodulin binding domain has also been identified in the main cytosolic loop of the NCXs (183) , but no convincing evidence has so far been provided that the regulation of the exchangers by Ca 2ϩ -calmodulin occurs in the ambient of the cell. Naturally, the autoregulation of the Ca 2ϩ signal by the interaction of calmodulin with the PMCAs (and, possibly, with the NCXs) is reversible and is expected to occur in response to the varying physiological demands of cells. However, irreversible autoregulation, e.g., inhibition under pathological conditions of Ca 2ϩ overload, could also occur, creating a vicious loop that augments the Ca 2ϩ overload itself. This is, for instance, the case for NCX3, which is cleaved and inactivated by calpain, which becomes activated under conditions of neuronal excitotoxicity that increase the influx of Ca 2ϩ (15, 38) . Calpain, however, also cleaves COOH-terminally, and activates, the PMCAs. The process has been extensively studied in vitro but could occur in conditions of spontaneous pathology as well (258) .
B. Ambivalence
Having chosen Ca 2ϩ as a determinant for function, cells benefit greatly from its practically unlimited availability in the external spaces. However, the choice forces them to live in a perpetual situation of controlled risk, that exposes them to the danger that amounts of Ca 2ϩ much in excess of those they could control will penetrate from the external spaces and persist in the cytosol.
Increases of the basal free concentration of Ca 2ϩ in the cytosol at rest significantly exceeding the optimal concentration of 100 -200 nM could only be tolerated for a short time. Transient increases of Ca 2ϩ above (even much above) the resting 100 -200 nM level may be necessary in some physiological circumstances and in selected cell microdomains, but in these cases, the delivery of the Ca 2ϩ message occurs in the form of rapid repetitive transients. The oscillations are a convenient device to satisfy the demands of cell functions that may require a brief increase of Ca 2ϩ concentration much above the normal level. But sustained increases to such levels would lead to the permanent activation of detrimental enzymes like proteases, phospholipases, and nucleases, and would lead to various degrees of cell discomfort, up to death in extreme cases. The negative outcome of the protracted global increase of Ca 2ϩ much above the normal level illustrates very clearly the ambivalent nature of the Ca 2ϩ signal, which had already been recognized in early Ca 2ϩ research: a number of now classical contributions (see Ref.
90 for a detailed review of the topic) had indeed shown cell death to be associated with abnormal increases of cell Ca 2ϩ . The pioneering work on heart must specifically be mentioned in this context (92) , but the observations were soon extended to other cell types (54, 211, 229) .
The increase of cell Ca 2ϩ much above the normal resting level does not inevitably seal the fate of cells if it only lasts for a limited time: a safety device helps cells to temporarily cope with such situations. This is the Ca 2ϩ uptake system of mitochondria, which has low Ca 2ϩ affinity, and only becomes activated when the cytosolic Ca 2ϩ in their surroundings approaches the micromolar range. Under normal conditions in most cells, the role of the mitochondrial uptake system is that of regulating three Ca 2ϩ -sensitive dehydrogenases in the matrix that are essential for the operation of the citric acid cycle, and thus for the synthesis of ATP. However, mitochondria can store much larger amounts of Ca 2ϩ in the matrix without dangerously increasing its osmotic concentration. This is so because they can accumulate inorganic phosphate alongside with Ca 2ϩ , precipitating in the matrix deposits of hydroxyapatite, thus making room for the uptake of more Ca 2ϩ . Interestingly, the hydroxyapatite deposits in the matrix do not crystallize but remain amorphous, thus facilitating their dissolution and the release of Ca 2ϩ from mitochondria once the emergency that had caused the cytosolic Ca 2ϩ overload has disappeared. However, the mitochondrial safety device only has temporary efficacy, as mitochondria use the same energy (the membrane potential across the inner membrane) to take up Ca 2ϩ or to synthesize ATP. As long as they are forced to continuously accumulate Ca 2ϩ , they will not synthesize ATP, eventually depriving the Ca 2ϩ pumps of the energy necessary to remove Ca 2ϩ from the cytosol, thus triggering a vicious loop that will exacerbate the Ca 2ϩ overload (38) . Ca 2ϩ catastrophe is the extreme case of the protected global Ca 2ϩ overload. Naturally, the concept only applies to the unwanted, toxic death of cells. It does not apply to the programmed cell death, which is sometimes a necessary outcome, for instance, in organ remodeling and cell pruning. Programmed cell death is thus but one of the meaningful ways to translate the Ca 2ϩ signal. However, apart from the unwanted (toxic) cell death, the ambivalence of the Ca 2ϩ signal is also illustrated in less dramatic ways by conditions in which the disturbance of Ca 2ϩ regulation is not massive, but subtler, as it only destabilizes individual participants in the Ca 2ϩ -controlling operation. Such conditions, which are mostly genetic, are still compatible with cell life but generate diverse paradigms of cell discomfort. They may be caused by defects of Ca 2ϩ sensor proteins, of Ca 2ϩ channels, or of the various Ca 2ϩ transporters. A number of reviews (38, 203, 252) and a recent book (41) offer a general coverage of this rapidly expanding area.
This review discusses in detail the conditions that originate from dysfunctions of Ca 2ϩ pumps.
III. Ca 2؉ PUMPS: GENERAL INTRODUCTORY CONCEPTS
Three Ca 2ϩ -ATPases (pumps) have been described in the cells of higher animals. They are located in the membranes of endo(sarco)plasmic reticulum, including the nuclear envelope, which is an extension of the latter (the SERCA pump), in those of the Golgi network (the SPCA pump), and in the plasma membrane (the PMCA pump). However, the Golgi membranes also contain the SERCA pump. Interestingly, the SPCA of the Golgi membranes also transports Mn 2ϩ , which is a cofactor of a number of enzymes in the lumen of the Golgi compartment. Plant cells, and cells of lower eukaryotes, e.g., yeasts, contain additional Ca 2ϩ pumps. They have interesting properties, but are not discussed in this review, as its focus is on the disease processes linked to the dysfunction of mammalian pumps.
All three animal Ca 2ϩ pumps belong to the family of P-type ATPases, which is characterized by the temporary conservation of ATP energy in the form of a phosphorylated enzyme intermediate (hence P-type) (235) formed between the ␥-phosphate of hydrolyzed ATP and an invariant D-residue in a highly conserved sequence in P-type ATPases: SDKTGT[L/I/V/M][T/I/S]. The P-type ATPases have now grown in number to form a large superfamily that contains at least eight subfamilies, and hundreds of members. A large number of sequences are now available: they have a low (ϳ15%) degree of general identity to each other. However, eight conserved regions that define the core of the superfamily have been identified (14) . Subfamilies have been identified based essentially on substrate specificity, the appearance of which in evolution has been accompanied by abrupt changes in sequence. Five branches have been identified in the phylogenetic tree: the Ca 2ϩ -ATPases belong to subgroups IIA (the SERCA and the SPCA ATPases) and IIB (the PMCA ATPase) (Fig. 1) . Naturally, the three Ca 2ϩ pumps share the essential basic properties, including membrane topology and reaction mechanism, and probably also the general features of the three-dimensional (3D) structure. This, however, is only a plausible prediction, as only one 3D structure, that of the SERCA pump, has so far been solved (296, 297) . The three pumps, however, also display significant sequence differences, particularly in areas not directly related to the molecular mechanism of catalysis, but related to regulation, action of some inhibitors, and role in cellular processes.
A simplified reaction scheme, the basic lines of which are valid for all three Ca 2ϩ pumps, is shown in Figure 2 . Originally, the scheme envisaged two conformational states of the pumps: the E1 state, in which the enzyme has high Ca 2ϩ affinity and interacts with Ca 2ϩ at one side of the membrane, and the E2 state, in which the lower Ca 2ϩ affinity leads to the release of the ion at the opposite side (60) . More recent structural work on the SERCA pump has increased the complexity of the conformational transitions that occur during the catalytic cycle. Upon binding of Ca 2ϩ , a series of structural changes occur that involve both the protruding cytoplasmic sector and the transmembrane domains, permitting the phosphorylation of the catalytic D-residue by the ␥-phosphate of ATP. The dissociation of Ca 2ϩ from the enzyme follows the transition of the high Ca 2ϩ affinity E1ϳP(Ca 2ϩ ) enzyme to the lower affinity E2-P enzyme, the hydrolysis of which then regenerates the Ca 2ϩ -free E2 ATPase, completing the catalytic cycle. The three pumps are all inhibited by the general inhibitors of P-type ATPases La 3ϩ and orthovanadate [VO 3 (OH)] 2Ϫ . However, in the case of La 3ϩ , differences exist: La 3ϩ accelerates the dissipation of the aspartyl phosphate in the SERCA and SPCA pumps, but increases instead its steady-state concentration, i.e., it stabilizes it, in the PMCA pump. The difference is experimentally useful, as it permits to identify the PMCA pump by using 32 P-gels in mixed preparations contaminated by even large amounts of the other two pumps.
FIG. 1. Phylogenetic tree of Ca
2ϩ -transporting ATPases. Protein sequences of P-type ATPases of different species were aligned using ClustalW software, and a phylogenetic tree was generated using TreeView. The three different branches represent the three main Ca 2ϩ -ATPase: SERCAs and SPCAs (type IIA) and PMCAs (type IIB).
The solution of the 3D structure of the SERCA pump has confirmed the existence and molecular nature of the two Ca 2ϩ binding sites in the transmembrane helices which had been predicted by mutagenesis work (56, 57) . The two sites are formed by residues (many of them acidic) in transmembrane domains 4, 5, 6, and 8 (see below). However, the existence of two Ca 2ϩ binding sites is peculiar of the SERCA pump: the PMCA pump lacks an essential acidic residue in transmembrane domain 5, and thus only has one Ca 2ϩ binding site that appears to correspond to site 2 in the SERCA1 pump. This explains the difference in Ca 2ϩ /ATP transport stoichiometry, which is 2.0 in the SERCA pump, but only 1.0 in the PMCA pump. The SPCA pump also lacks the essential acidic residue in transmembrane domain 5, and thus only has Ca 2ϩ (and Mn 2ϩ , see below) binding site 2, and 1:1 stoichiometry between hydrolyzed ATP and transported Ca 2ϩ (or Mn   2ϩ ).
A. The SERCA Pump
General properties
The first ATP-driven Ca 2ϩ transport system, which was later identified as the SERCA pump, was discovered in 1961-1962 in a skeletal muscle fraction known at the time as the Marsh relaxing factor. The fraction, which was later shown to correspond to the vesicles of sarcoplasmic reticulum (SR), accumulated Ca 2ϩ at the expenses of the hydrolysis of ATP (78, 123) . The process was suggested to involve an ATP-driven pump that was purified some years later as a protein of ϳ110 kDa (193) . Important features of the transport process, including its reversibility, were established by the early studies: SR vesicles that had accumulated Ca 2ϩ mediated the synthesis of ATP when incubated with ADP in the absence of Ca 2ϩ (123) . Initially, the transport process was studied on the SR of skeletal and cardiac muscles, but the work was later extended to the endoplasmic reticulum (ER) of all cells. SR, however, remained a preferred object of study, thanks to the abundance of the transporting pump in its membrane (up to 90% of the total protein), which facilitated its isolation and purification.
The pump was soon recognized as the main system for the control of cytoplasmic Ca 2ϩ in muscle cells, where its ability to remove Ca 2ϩ from the cytosol induced relaxation. Studies in the early period showed that the pump transported two Ca 2ϩ per ATP hydrolyzed and that it countertransported H ϩ in exchange for Ca 2ϩ . However, fewer than four H ϩ were released to the cytosol per two Ca 2ϩ pumped, showing that the transport reaction was partly electrogenic. This electrogenic mechanism could thus be responsible for the alkalization of the luminal side of the ER/SR (328) . It was soon discovered that, as all P-type pumps (see above), the SERCA pump was inhibited by La 3ϩ and orthovanadate (284) . Specific inhibitors were soon also discovered: thapsigargin (isolated from the roots of Thapsia garganica) (290) , cyclopiazonic acid (produced by Aspergillus and Penicillum) (272) , and 2,5-di(t-butyl)hydroquinone (227) . Curcumin [diferuloylmethane, or 1,7-bis(4-hydroxy-3-methoxyphenol)-1,6-hepatadiene-3,5-dione], a compound derived from the spice turmeric which is presently attracting considerable attention for its antitumoral action, also inhibits the pump, probably by stabilizing the interaction between the nucleotide-binding and phosphorylation domains, thus precluding ATP binding (22) . However, its specificity is lower than that of the other inhibitors, as it may also interfere with the intracellular Ca 2ϩ release channels (77) . Cyclopiazonic acid (CPA) and 2,5-di(t-butyl)hydroquinone (tBHQ) have lower affinity for the pump than thapsigargin (K d in the low micromolar to high nanomolar range). Although less is known about their mechanisms of action than about that of La 3ϩ and orthovanadate, a number of indications suggest that they probably compete with ATP. Interestingly, recent studies on the structure of the SERCA-CPA complex (205) have shown that CPA occupies the Ca 2ϩ access channel in the pump molecule. While the inhibition by CPA and tBHQ is reversible, and disappears following their removal, that by thapsigargin (TG), is irreversible. TG is the most popular inhibitor of the SERCA pump, and its mechanism of action is better characterized than that of the other inhibitors. It binds stoichiometrically to F256 in the M3 helix (327) , locking the pump in an irreversible inactive state (256 which has been advantageous when solubilizing the pump protein for structural work, as it prevents its denaturation. It has permitted to obtain the 3D structure of the pump structure in the Ca 2ϩ -free (E2) state (297) and has helped to clarify the conformational changes occurring during the reaction cycle.
The cloning of the SERCA pump cDNAs (26, 34, 192, 194) has permitted to reach a number of conclusions on the molecular mechanism of the pump. It has also led to the proposal that the enzyme is organized in the membrane with 10 transmembrane helical domains (M1-M10) and has allowed the manipulation of the pump by sitedirected mutagenesis. A number of predictions on the structure and mechanism of the pump made in the early studies have then been validated by the solution of its 3D structure at the atomic level in 2000 (296) . The structure has permitted to decipher the details of the reaction cycle that culminates with the transit of Ca 2ϩ across the pump protein. Its general aspects are briefly discussed here as they are most likely paradigmatic for the molecular operation of the two other Ca 2ϩ pumps. The structure has shown that the single polypeptide chain of the pump folds in four major domains (Fig. 3 ): a transmembrane (M) domain, indeed composed of the 10 predicted transmembrane helices (M1-M10), and three cytosolic domains. Two of them, the actuator domain (A) and the phosphorylation (P) domain, are connected to the M domain. The nucleotide-binding (N) domain, instead, is connected to the P domain.
During Ca 2ϩ binding and translocation, a number of large conformational changes switch the "compact" structure of the cytosolic portion of the pump to a more "open" structure ( Fig. 3) (294) . Before translocation, Ca 2ϩ becomes bound to two sites, (site I and site II) in the M domain. As had been predicted, the binding sites, which are located side by side closer to the cytoplasmic surface of the membrane, exist in high-and low-affinity states. The first allows access of Ca 2ϩ from the cytosolic side (E1 state), and the second, in which the sites face the luminal side of the membrane (E2 state), favors the release of Ca 2ϩ . The binding of Ca 2ϩ to the two sites occurs sequentially. Site I is located between M8 and M5, and site II between M6 and M4. In both sites, Ca 2ϩ coordinates seven oxygens of residues in M4, M5, M6, and M8: side chain oxygens of N768, E771 (M5), T799, D800 (M6), and E908 (M8) together with two water molecules form site I. Site II is located slightly closer to the cytoplasmic surface nearly on the M4 helix, which provides the two side-chain oxygens of E309 and three carbonyl oxygens to the coordination of Ca 2ϩ . N796 and D800 (which contributes to the formation of both sites) in M6 complete site II by donating one side chain oxygen each. The molecular path for Ca 2ϩ across the pump protein has been mapped and is shown in the cartoon of Figure 4 : the first Ca 2ϩ would enter the binding cavity through gating residue Glu 309, positioning D800 to induce the rotation of M6 and, possibly, the straightening of the M5 helix. This would rearrange coordinating oxygens of site II to form a higher affinity site (E23 E13 E1⅐2Ca 2ϩ transition). At this point, the side chain of E309 would cap site II Ca 2ϩ , mechanically transmitting the binding signal to the phosphorylation site ϳ50 Å away. The straightening of the M5 helix would loosen up the compact configuration of the three cytoplasmic domains, which prevents the delivery of the ATP bound to the N domain to the catalytic D in the P domain. The binding of Ca 2ϩ also increases the tilting of the N domain, separating the P and A domains, permitting the delivery of ATP to the D315 phosphorylation site (E1⅐2Ca 2ϩ 3 E1P transition). The binding of ATP crosslinks the P and N domains, bending the former to make contact with the A domain. The strain rotates the A domain, pulling up and bending the M1 helix, that closes the cytoplasmic E309 gate occluding the two bound Ca 2ϩ . The transfer of the ␥-phosphate of bound ATP to the catalytic aspartate then dissociates bound ADP, opening the N-P domain interface. The rotation of the A domain rearranges helices M1-M6, opening the luminal gate for the release of the occluded Ca 2ϩ (E1P3 E2P transition). H ϩ and water molecules stabilize the liberated Ca 2ϩ binding sites, and at this point, a second rotation of the A domain electrostatically locks it to the P domain, closing again the luminal gate (E2P3 E2⅐P i transition). The A domain contains the highly conserved TGES sequence: the rotation of the A domain retracts the side chain of E183 from the phosphorylation site, inducing a conformational change in the TGES loop that permits the entrance of a water molecule in the phosphorylation site to hydrolyze the aspartylphosphate. The release of the phosphate (and of Mg 2ϩ ) then relaxes the P domain completing the closing of the luminal gate.
Isoforms of the SERCA pump
In mammals, three genes (human nomenclature ATP2A1-3) encode three main SERCA proteins. Each of the three transcripts undergoes tissue-dependent alternative splicing, increasing the number of pump variants ( Fig. 5 offers a comprehensive view of all splicing processes). The changes in the expression pattern of the variants during development and tissue differentiation indicate that each isoform is adapted to specific functions. SERCA1a and SERCA1b variants are expressed in adult and neonatal fast-twitch skeletal muscles, respectively. The SERCA2a variant is selectively expressed in heart and slow-twitch skeletal muscles, whereas the SERCA2b variant is expressed nearly ubiquitously and is thus considered the housekeeping isoform. SERCA3 is instead expressed in a limited number of nonmuscle cells. SERCA1 was the first pump to be studied, owing to the relative ease with which it could be purified, and it was the first member of the family to be cloned. Since it has been used for the 3D work mentioned above, it is the best understood SERCA pump isoform. The SERCA1 gene contains 23 exons, and the two isoforms that have been described result from the alternative splicing of exon 22 (42 bp) , that is removed in SERCA1b. In neonatal SERCA1b, a highly charged sequence of eight amino acids replaces the E994 residue that is found in the adult form: the functional meaning of this difference is still unknown. Two other human transcripts have been recently described that originate from a splicing operation in the 5Ј region. They generate SERCA1T and SERCA1Tϩ4, which are two truncated 46-kDa versions of the pump, understandably unable to transport Ca 2ϩ (48) . As mentioned, SERCA2 is distributed widely, and this is probably why it has a larger number of modulator factors. It is the oldest SERCA pump, and its two isoforms are the product of four different mRNAs. One of them is translated into the SERCA2a protein, while the other three, which only differ in the 3Ј-untranslated region, encode SERCA2b. The human SERCA2 gene contains 22 exons. In SERCA2a, exon 21 is spliced out and the first part of exon 20 is joined to exon 22. In SERCA2b, exon 20 is extended and contains an alternative stop codon and three different noncoding regions. Recently, the mRNA of a new SERCA2 isoform (2c) has been detected in human monocytes and fetal hearts (100) . It results from the inclusion of a short coding sequence (a new exon 21 or exon SERCA2c) containing an in-frame stop codon. The SERCA2c protein could possibly have functional importance in (fetal) heart as its expression predominates in the left ventricle (59); however, the variant has also been detected in skeletal muscles. The sequence of the three SERCA2 isoforms is identical for the first 993 amino acids. Then, four amino acids in the COOH-terminal region of SERCA 2a are replaced by 49 amino acids in the 2b variant and by 6 in the 2c protein. Interestingly, the extended COOH terminus of the SERCA2b pump contains a highly hydrophobic segment that has been proposed to form an additional (11th) transmembrane domain (16) . The divergence in the COOHterminal portion of the three SERCA2 variants is responsible for functional differences (312) . The expression of SERCA2a and SERCA2b in model cells has shown that the latter had higher affinity for Ca 2ϩ but lower catalytic turnover rate (68, 190, 310, 311) . Both isoforms have the same sensitivity towards phospholamban (191) (see below). SERCA2c has even lower Ca 2ϩ affinity than the 2a variant, possibly because it operates in an ambient of particularly high [Ca 2ϩ ] concentration (59) . The physiological meaning of the SERCA2a/2b diversity was recently investigated (310) in transgenic mice in which the 2a isoform was replaced by the 2b. The phenotype was characterized by cardiac malformations and by a 40% increase in embryonic and neonatal mortality. The adult mice developed compensatory left ventricular hypertrophy with impaired cardiac contraction and relaxation. Apparently, then, the SERCA2a isoform is critical for the correct development and function of the heart. The SERCA3 pump is less well understood, and the issue of its alternative splicing isoforms is rather complex, as documented by Figure 5 . The numeration of the exons in SERCA3 gene is also confusing, since, as in SERCA2 gene, exons 8 and 9 are fused together, thus generating one "double" exon. In humans, six possible SERCA3 variants (a-f) have been described (23, 322) . The SERCA3 gene is organized in 22 exons, and the alternative splicing of exons 20 and 21 generates the 6 variants, which differ in the COOH-terminal portion. All transcripts retain exon 22, but the a variant excludes exon 20 and 21, the b-c variants retain a portion of or all exon 20 and exclude exon 21, variants d-e retain a portion of or all exon 20 and 21, and, finally, the f variant excludes exon 20. So far, only the a-c isoforms have been documented as proteins.
All documented variants (a-c) have markedly lower apparent affinity for Ca 2ϩ than the other basic isoforms, 10-fold higher apparent affinity for vanadate, and do not react with phospholamban (see below). The SERCA3 pump (see below) seems to be specialized for the control of relaxation of vascular and tracheal smooth muscle. The lower Ca 2ϩ affinity suggests that the SERCA3 pump would only become active when cytosolic Ca 2ϩ reaches abnormally high levels, e.g., after massive cell stimulation with Ca 2ϩ -linked agonists. Interestingly, the SERCA3 pump is almost always coexpressed with the housekeeping SERCA2b, and no obviously pathological phenotype follows the ablation of its gene (188) .
If the structure-function relationships are best understood in the SERCA1 isoform, the regulation aspects are instead best understood in the SERCA2 isoform. Therefore, in discussing modulatory protein partners for SERCA pumps, most of the information necessarily concerns SERCA2 interactors. The best known interaction with a regulatory protein is that with phospholamban (PLB), which was described in the heart nearly 40 years ago (13, 149, 156) . The involvement of PLB in the regulation of the pump, and its site of interaction with it, which was initially characterized by cross-linking experiments (137), were later explored by site-directed mutagenesis (293) and further defined through molecular modeling approaches (135, 169, 233, 295) . As mentioned, PLB interacts with SERCA1a, SERCA2a, and SERCA2b but not with SERCA3. The tertiary structure of PLB shows that it has a hydrophobic helical COOH-terminal portion intrinsic to the SR membrane and a hydrophilic NH 2 -terminal portion that protrudes into the cytosol (169): in its unphosphorylated form, it binds to the pump and inhibits it by reducing its apparent Ca 2ϩ affinity. The binding occurs to three sites. One is the sequence K397DDKPV in the cytosolic N domain of the pump, which interacts with the hydrophilic portion of PLB (292) . The sequence is conserved in the SERCA1 and -2 proteins but not in SERCA3. Another site of the pump is the L67 loop (9), which interacts with the cytosolic portion of PLB and the M6 helix which interacts with its transmembrane domain (10) . A third site of interaction has been identified close to the M4 helix by crosslinking experiments between a PLB in which N30 had been mutated to C, and C318 in the SERCA pump (144) . Phosphorylation of the hydrophilic portion of PLB by protein kinase A (PKA) (S16) (and/or calmodulin-dependent kinase II, CaMKII on T17) is presumed to detach PLB from the pump, increasing its affinity for cytosolic Ca 2ϩ and reactivating Ca 2ϩ uptake. However, it has also been proposed that phosphorylated PLB would still remain associated with the pump (209), possibly through the interaction of its NH 2 -terminal domain with the site in the N domain. The physiological importance of PLB regulation in muscle contractility is now well established and has been repeatedly discussed in reviews (195) . The generation of mice models with altered PLB expression levels has indicated that the downregulation of PLB increases the affinity of SERCA2a for Ca 2ϩ and heart contractile parameters, whereas its cardiac overexpression is associated with a significant impairment of heart function (146, 189) (see below).
Another small transmembrane protein, sarcolipin (SLN), has recently received attention as a PLB homolog that would regulate SERCA1 pump activity in skeletal muscles (221) . Recent observations have demonstrated that SLN is coexpressed with SERCA2a and inhibits it. The coexpression of SLN and PLB in model cells leads to pump superinhibition. At variance with PLB, the physiological significance of the regulation of the SERCA pump by SLN is still obscure.
The SERCA2 pump also plays a critical role in maintaining the Ca 2ϩ concentrations in ER/SR. Changes in its activity may thus affect a number of ER/SR functions, including protein synthesis and maturation. In turn, a number of Ca 2ϩ -binding luminal proteins are believed to control the activity of the SERCA2 pump. Studies on Xenopus laevis oocytes have demonstrated that the ER chaperons calreticulin and calnexin regulate the activity of the SERCA2 pump from the lumen, shaping the InsP 3 -induced Ca 2ϩ oscillations (36, 143) . Calreticulin has been suggested to functionally interact with SERCA2b but not with SERCA2a (143) . Unlike SERCA2a, SERCA2b contains an N-glycosylation site in its luminal COOH-terminal portion. It was thus proposed that the functional differ-ences of the two isoforms could be related to the interaction of the lectin domain of calreticulin or of calnexin with the glycosylated residue in SERCA2b. The matter is interesting but controversial, as glycosylation of residue N1036 has not been unambiguously demonstrated, whereas glycosylation-independent protein-protein interaction of SERCA2b may occur. In addition, the treatment with endoglycosidase H has failed to alter the electrophoretic mobility of the SERCA2b protein, suggesting that it was probably not glycosylated (253) .
The ER oxidoreductase Erp57, which participates in the quality control and the folding of newly synthesized proteins, also interacts with the intraluminal loop 4 of SERCA2b in a Ca 2ϩ -dependent manner. The interaction probably occurs through calreticulin and results in the inhibition of the pump, possibly through the modulation of the overall redox state of ER, since Erp57 promotes disulfide bond formation (182) . Depletion of ER Ca 2ϩ would displace Erp57 from SERCA2b, favoring disulfide bond reduction and stimulation of ATPase activity. SERCA2b might thus function as an ER redox sensor. Other interactions of the SERCA pumps have also been described. That with the luminal Ca 2ϩ binding protein sarcalumenin (SAR) in skeletal and cardiac muscle (SERCA1a) (73) has no clear physiological role, and that with the antiapoptotic protein Bcl-2 (SERCA1 and SERCA2) (74, 166) has been proposed to reduce ER Ca 2ϩ content through the inhibition of pump activity (74) . Other mechanisms could also link the antiapoptotic function to the ER Ca 2ϩ content, e.g., the formation of Ca 2ϩ leak channels by Bcl-2, or the role of Bcl-2 in the expression of SERCA pumps. The entire matter is still controversial (166, 303) , but the possibility of a role of the SERCA pump in the regulation of the apoptotic pathways cannot be discounted.
The insulin receptor substrate (IRS) proteins 1 and 2 also interact with the SERCA pump in a process that is stimulated by insulin. The interaction occurs at a COOHterminal site of SERCA1a and -2a (1), which is not conserved in the SERCA3 pump. Nevertheless, isoform 3b has also been proposed to interact with IRS proteins (24) , suggesting a general link between the tyrosine phosphorylation cascade and the effects of insulin on the homeostasis of Ca 2ϩ . IRS1 overexpression has been claimed to inhibit the expression of SERCA2 (165) and -3 (165, 325) pumps. Lastly, the EF hand protein S100A1, which is preferentially expressed in the myocardial tissue, coimmunoprecipitates with SERCA2 in a Ca 2ϩ -dependent manner (155) . The interaction with S-100 has been claimed to enhance pump activity in vitro and in vivo (207) . Interestingly, it has recently been proposed that the activity of the SERCA pump is physiologically regulated by the interaction with presenilin, the membrane intrinsic protein that localizes predominantly to the ER membrane (109) . Presenilin is the catalytic portion of the mutienzymatic complex of ␥-secretase, which is responsible for the generation of the amyloid ␤ fragment. The finding that the modulation of SERCA pump activity would alter amyloid ␤ production suggests a possible role of the SERCA pump in the pathogenesis of Alzheimer's disease.
Posttranslational modifications of the SERCA2 pump
Posttranslational modifications such as glycosylation, oxidation, and phosphorylation could also control SERCA2's pumping activity. The possible role of glycosylation in mediating the interaction of the SERCA pump with calreticulin and calnexin, as well as oxidation effects, have been mentioned above. Both may be linked to nitric oxide (NO), which can activate the pump in a cGMP-independent manner, and thus potentiate the relaxation of vascular smooth muscle, and of cardiac and skeletal muscles. The effect depends on the modification of reactive thiol groups on the SERCA protein and appear to require the presence of reactive oxygen species (ROS). Accordingly, it is thus attenuated by the overexpression of superoxide dismutase (SOD1). Indeed, the SERCA2 pump is remarkably sensitive to oxidative damage, and even its expression is downregulated by the oxidative stress (158) .
A direct, CaMKII-dependent phosphorylation effect has been described on the V max of the cardiac SERCA2 pump, but not on that of SERCA1, which lacks the CaMKII consensus site RXXS/T (124). The kinase, however, only phosphorylated a minor fraction of the pump molecules (Ͻ20%), casting doubts on the physiological relevance of the finding (124, 324) . The doubts were strengthened by other studies in which pump phosphorylation was not detected or was not accompanied by stimulation (222).
The SERCA pumps in the disease process
Two human genetic diseases associated with mutations in the SERCA pump genes have been described so far, but gene inactivation studies in mice have revealed additional pathological phenotypes distinct from those of the human diseases. The two human diseases (Brody's and Darier's disease) will be described first. Other dysfunctions of the pump related to defects in its activity or expression level, i.e., heart failure and cancer development, will then be discussed.
Brody's disease is a rare recessive muscular condition characterized by impaired relaxation, painless cramps, and stiffness following exercise (29) . The clinical diagnosis is difficult, since the symptoms are rather heterogeneous and nonspecific. The activity of the SERCA1 pump has been reported to be reduced in biopsies of the quadriceps muscle and in cultured muscle cells. In some cases, decreased SERCA1 expression in fast-twitch muscles has also been detected (18, 148) . The disturbance of the SERCA1 pump seems to be specific, since the fiber-type distribution and the total protein content of the muscle are modified with respect to control muscles. Three mutations in the SERCA1 gene had been originally identified in two affected families (223) . One occurred at the splice donor site of intron 3, and the other two created premature stop codons, truncating the pump and thus deleting essential domains. Three other mutations leading to premature stop codons and an inactivating missense mutation were also later identified in a total of six families (220, 224) . The patients could still relax fast-twitch muscles, although at a significantly reduced rate. This suggests that some compensation by ectopic expression of SERCA2 or SERCA3, and/or by Ca 2ϩ removal from the cytosol by the PMCA pump and the Na ϩ /Ca 2ϩ exchanger could limit the defect in the Ca 2ϩ clearing activity of the SR. The recovery phase of resting cytosolic [Ca 2ϩ ] after acetylcholine stimulation in cultured muscle cells was slower than in control cells.
Interestingly, a missense mutation (in exon 6 of the gene) leading to the R164H replacement has been very recently identified in Chianina cattle suffering from congenital pseudomyotonia, a muscle function disorder very similar to that of Brody's disease (75) . The disorder is characterized by muscle contractures that occur when the animals are forced to move fast, or are exposed to stresses that induce escape behavior. The content of the SERCA1 protein in affected muscles was found to be sharply reduced (up to 90%), whereas that of its mRNA was not; thus a defect in transcription was apparently not involved (255) . R164 is located in the A domain of the pump, where its side chain could neutralize the negative charge of neighboring E2 during the large movement of the A domain in the E1-E2 transition. The replacement of the R side chain with the imidazole side chain of H would destabilize the E2 state, possibly enhancing the susceptibility of the protein to degradation (G. Zanotti, personal communication) (172) . It is of interest that an R164S mutation has also been found in a Darier's disease Hungarian patient (see below) (243) . Another missense mutation in the SERCA1 gene has recently been found in Belgian Blue cattle affected by congenital muscular dystonia 1 (51) . Affected calves show impaired swallowing fatigue upon muscular exercise or stimulation, inability to flex limbs, injurious falling, and die after a few weeks because of respiratory problems. The mutation affects exon 14 of the gene and leads to the replacement of a very conserved R (R559) with a C in domain N. No functional analysis of the SERCA1 activity has so far been performed on the muscles of affected Belgian Blue cattle, but the role of the conserved R has been analyzed in rabbit muscles (131) . R560 (corresponding to bovine 559 in rabbit muscle) could interact with the ␤-phosphate moiety of ATP (131) as it lies close to the nucleotide binding pocket of the N domain. The positive charge of the R could thus contribute to the stabilization of the substrate. Replacement of R560 with an A (131) produced a strong inhibition of the ATPase activity and of the phosphoenzyme formation from ATP.
Darier's disease (or Darier-White's disease) is a rare autosomal dominant skin disorder characterized by loss of adhesion between epidermal cells and abnormal keratinization (33) . The disease is characterized by keratotic papules in seborrhoic areas of the skin and in the skin flexures which can then form confluent plaques. The first lesions often appear at puberty, have a chronic relapsing course, and are exacerbated by sunlight or ultraviolet irradiation, heat, sweating, friction, and infections. The histology of the condition shows loss of cell-to-cell adhesion in the suprabasal layer (suprabasal acantholysis) and abnormal keratinization (dyskeratosis) (Fig. 6 ). Apoptotic keratinocytes are thought to become eosinophylic dyskeratotic cells (grains) (101, 108, 161, 236, 319) .
More than 130 mutations in the SERCA2 gene have now been reported in human patients. The mutations are distributed across the entire pump molecule, with no evidence of clustering or of mutation hot spots. Interestingly, while the majority of Darier's disease patients harbor mutations in a region which is common to 2a and 2b isoforms, three families with classical Darier's disease were heterozygous for a mutation located in a region of exon 20 which is specific for SERCA2b (67, 136) . These mutations led to premature termination codons and inactivated the pump, indicating that the suppression of SERCA2b activity was sufficient to determine the pathological phenotype, i.e., the expression of SERCA2a could not compensate for it. The overexpression of recombinant mutated pumps in model cells has revealed that in the large majority of cases the mutations indeed impaired their ability to transport Ca 2ϩ . However, reduced pump expression, probably due to protein instability, has also been observed in some cases.
Symptoms like behavior and learning difficulties, which have been observed in some patients with Darier's disease, are probably secondary. Surprisingly, instead, no reports have described heart defects, in spite of the finding that the large majority of patients carry mutations in the region of SERCA2 gene which is common to both SERCA2a and -2b isoforms.
Keratinocytes from Darier disease patients have lower ER Ca 2ϩ content but show a normal Ca 2ϩ response to raised extracellular Ca 2ϩ concentration, a condition that determines their differentiation. This has been attributed to the compensatory overexpression of the SPCA pump (93) . The resting cytosolic Ca 2ϩ concentrations varied in different patients (93) , but in one report, cytosolic Ca 2ϩ in cultured keratinocytes was instead found to be increased (179) . These keratinocytes were practically incapable of lowering cytosolic Ca 2ϩ after treatment with thapsigargin and responded to the stimulation of purinergic receptors with a reduced elevation of cytosolic Ca 2ϩ (179) .
The depleted ER Ca 2ϩ store in Darier's keratinocytes could alter the posttranslational processing of proteins in the secretory pathway and limit their sorting to the plasma membrane, thus contributing to the triggering of the ER stress response. This would be in keeping with the exacerbation of lesions induced by stressing factors. The sorting of the tight junction protein ZO-1 and of the desmosomal protein desmoplakin were indeed strongly inhibited by thapsigargin in a MDCK cell model for intracellular junction assembly (282) . A study on Darier's keratinocytes has confirmed the inhibition of the trafficking of desmoplakin to the plasma membrane. Interestingly, the defect was found to be specific for desmoplakin, as two other desmosomal proteins, desmoglein and desmocallin, were instead efficiently sorted to the plasma membrane (66) .
An important factor to be considered in the molecular pathology of Darier's disease would be the epidermal Ca 2ϩ gradient, which could become disrupted as in Hailey-Hailey's disease, a similar acantholytic skin disorder linked to inactivating mutations in the gene of SPCA pump and/or to the reduced level of its expression (see below for details). The Ca 2ϩ gradient and the role the SERCA pump defect could have in its possible disruption in Darier's disease have not been studied as yet.
The reason for the restriction of the clinical symptoms of Darier's disease to the epidermis and to certain areas of the skin is not clear: it is probably related to the fact that the SERCA3 pump, which is coexpressed with SERCA2b in a large variety of cells, is not expressed in the epidermis and may thus fail to provide compensation in cutaneous tissues. Darier's disease shares features with Hailey-Hailey's disease, which is also characterized by a loss of adhesion between keratinocytes and by abnormal keratinization of the epidermis (see below). Thus it appears that the SERCA and SPCA pumps cooperate in maintaining Ca 2ϩ homeostasis in the keratinocytes and that the imbalance of their activity compromises Ca 2ϩ homeostasis and, in the absence of compensatory factors, leads to clinical phenotypes.
Other diseases related to alterations of the SERCA pumps
Other disease phenotypes linked to alterations in the expression of the SERCA pump have also been described. The SERCA pump is functionally decreased in nearly all models of heart failure (see Ref. 163 for review), and decreased SR Ca 2ϩ transport and SR Ca 2ϩ content have been detected in animal heart failure models. Although heterogeneity in the expression level of the SERCA pump has been observed in failing hearts, it is generally accepted that a reduction of the SERCA2a protein levels (and/or activity) plays a role in the development of the failure condition. The level of the SERCA2a regulator PLB is not altered in heart failure, but data have been reported suggesting that its phosphorylation state may be reduced (132, 249, 270) . This would explain the lower activity of the SERCA pump. Surprisingly, only one report has described naturally occurring mutations in the human SERCA2 gene that may predispose to heart failure (262). However, the mutations, which occur in the exons corresponding to the SERCA2-PLB interaction domains, did not result in sequence alterations in the expressed protein, suggesting that the SERCA2 gene is tightly regulated to maintain low genetic variation. In contrast, three mutations in the coding region of the PLB gene have been described which appear to be inherited in a familial manner. The R9C mutation was associated with the inheritance of dilated cardiomyopathy (263) , resulted in the decrease of phosphorylation of PLB, and induced dilated cardiomyopathy and early death when introduced in transgenic mice. A second mutation (L39stop), detected in two large families (94) , was also associated with dilated cardiomyopathy. Several lines of evidence have indicated that the L39stop mutation had no effect on SERCA2a activity, nor on the mechanics and Ca 2ϩ cycling of the myocytes; however, the mutant PLB was not detected in human homozygous ventricles. A third human mutation (deletion of R14) has also been recently associated with dilated cardiomyopathy (quoted in Ref. 163) . As discussed in Kranias and Bers (163) , the human PLB mutations resulted in dilated cardiomyopathy and eventual heart failure from the inhibition of the basal or the ␤-adrenergic stimulated SERCA2a activity in the R9C and R14del mutations. In the L39stop mutation, which did not alter the activity of the SERCA pump but caused the absence of PLB, heart failure would be caused by the fact that in humans hearts the regulation of SERCA pumping by PLB is essential for normal function, due to the large cardiac reserve required for the flight-or-fight situations that would allow two-to threefold increases in heart rate.
A relationship between cancer and SERCA pump dysfunction has been repeatedly documented: it is acquiring special interest, as accumulating evidence now indicates that the altered cellular homeostasis of Ca 2ϩ may be involved in the abnormal cell proliferation that is a hallmark of the malignant transformation. The matter has aspects that are seemingly paradoxical: on one hand, the increase of cytosolic Ca 2ϩ , e.g., by hyperactivated plasma membrane channels, promotes cell proliferation. On the other hand, situations of Ca 2ϩ overload trigger apoptotic death pathways. Somehow, therefore, tumor cells regulate the cell signaling machinery to promote proliferation while at the same time protecting themselves from apoptosis. A remodeling of Ca 2ϩ homeostasis is thus increasingly considered important in the process of malignant transformation (see Ref. 206 for a review), and it is thus only to be expected that alterations of the expression and/or function of Ca 2ϩ regulators such as the Ca 2ϩ pumps should have a role in the process of tumorigenesis. Several reports have shown that ATP2A2 (SERCA2) haploinsufficient mice often developed cancer. Mutations in the ATP2A2 gene could be responsible for human cancer development. Thirteen alterations of the gene were found in patients with colon or lung cancer. They were missense mutations, intronic deletions or insertions, and singlenucleotide alterations (2 in the coding region, 3 in the intronic region, and 3 in the promoter region). Loss or reduced expression of SERCA2 was also detected in all patients with alterations in the promoter region of the gene, as well as in patients with combinations of gene alterations (159) . Similarly, eight different mutations have been found in the ATP2A2 and ATP2A3 genes in 11 patients with head and neck squamous cell carcinoma (160) , suggesting that germline alterations of these genes may predispose to cancer and that impaired SERCA genes might be involved, directly or indirectly, as an early event in carcinogenesis. Additional evidence for the involvement of SERCA pump defects in cancer comes from studies on the expression of pump isoform in some carcinoma and leukemia cell types during differentiation. The SERCA3 pump was significantly reduced or lost in colon carcinomas (99) . Treating colon and gastric cancer cells with differentiation-inducing agents markedly stimulated the expression of SERCA3 (not of SERCA2) (99) , and a similar overexpression of all three SERCA2 splice isoforms was detected during the spontaneous differentiation of Caco-2 cells. Treatment of KATO-III gastric cancer cells with differentiating agents concomitantly restored the increased cytosolic Ca 2ϩ to normal (99) . A similar study on colonic epithelium has shown that the level of SERCA3 pump expression correlated with the degree of malignancy, being high in normal cells, moderately decreased in adenomas, and barely detectable, or absent, in poorly differentiated tumors (30) . Similar observations, but on SERCA2, have been made in prostate cancer cells. The transformation of the human prostate cancer LNCaP cell line to androgen-independent phenotypes, which are characterized by increased malignancy and apoptotic resistance, resulted in the decreased expression of SERCA2b (305) .
In an interesting approach, SERCA pump inhibition by TG has been proposed as a potential targeted therapy for prostate cancer. As is well known, TG (or similar agents) induces the activation of apoptotic pathways within the ER and the mitochondria. Obviously, as SERCA is an ubiquitous protein, TG would be toxic and thus impossible to use in therapy. The toxicity problem has been eliminated in the approach by coupling TG to a carrier peptide, producing an inactive prodrug that would only become activated in the environment of prostate malignant cells. This is due to the fact that prostate cancer cells produce a specific antigen (PSA) that is a serinethreonine protease. In the prodrug, the carrier peptide that shielded the toxicity of TG was the peptide substrate of PSA, which would only be cleaved off efficiently from the inactive complex in the environment of the prostate cancer cells, where the PSA protease is abundant, liberating TG: prodrugs of this type, which are currently under preclinical evaluation, have yielded promising initial results (64) . Curcumin has also been proposed as an anticancer drug: thanks to its low toxicity it is now in phase II of clinical trials for advanced treatment of pancreatic cancer (2, 65) .
Interesting findings have demonstrated that the human hepatitis B virus (HBV) DNA integrates into the gene of SERCA1 pump in a liver tumor causing the expression of mutated proteins, which resulted in decreased ER Ca 2ϩ content and in the increase in apoptosis (49) . Viral integration was shown to cis-activate SERCA2 chimeric transcripts with the splicing of exon 4 and/or exon 11. The splicing of exon 11 created a frame shift and generated a premature stop codon in exon 12. The encoded protein lacked the main portion of cytosolic domains N and P and transmembrane segments M5 to M10. Predictably, it was unable to pump Ca 2ϩ . Splice variants similar to the mu-tated proteins were also expressed in normal liver, their overexpression increasing Ca 2ϩ leakage from the ER, and inducing apoptosis (48) . The findings reinforce the suggestion of a role of the SERCA pump in the control of cell death.
The expression of the SERCA3 pump in pancreatic ␤-cells, and the association of sequence variants of the pump with type II diabetes (306) , as well as the finding that SERCA pumping activity was impaired in diabetic rats model (181) have suggested that the SERCA3 pump could be involved in the Ca 2ϩ deregulation linked to the onset of diabetes and that it could contribute to the genetic susceptibility to type II diabetes. However, a direct link to insulin secretion, which could be mediated by modulating cytosolic Ca 2ϩ , has not yet been demonstrated.
A few words are in order on the recent finding that the most important class of antimalarial drugs, the sesquiterpene lactone artemisinins, would target the Plasmodium falciparum SERCA pump ortholog PfATP6 (80) . The drug was found to inhibit the Plasmodium pump, but not mammalian SERCA, with the same potency and stoichiometry of TG. The specificity of artemisinin for the plasmodium enzyme was found to be due to the replacement of a glutamic acid in transmembrane domain 3 of the mammalian pump with a leucine (L263E) (299) . If L263 of PfATP6 was replaced by an E, the pump became resistant to artemisinin, but retained the sensitivity to TG. Considering the social importance of malaria, these studies, even if still preliminary, deserve to be developed and expanded. The finding that artimisinin resistance can be introduced in PfATP6 is a matter of concern, and it will thus be important to identify the full repertoire of ATP6 residues that interact with artemisinins.
Genetic manipulation of the SERCA pumps
Knockout mice have been developed for all three SERCA pump isoforms. The study of their phenotypes has revealed unexpected differences between human and mice. Mice lacking the SERCA1 pump (231) were born alive and appeared to be initially normal. However, at variance with humans, in whom Brody's disease patients, which have no SERCA1 or markedly lower levels of it, have no respiratory ailments, null mice exhibited instead respiratory failure and died shortly after birth. They also exhibited slow limb movements and evidence of cramping. The Ca 2ϩ uptake activity in homogenates obtained from the diaphragm or hindlimb muscles of these mice was severely impaired, without compensation by SERCA2 and -3 isoforms. This confirmed the major role of the SERCA1 pump in maintaining the SR Ca 2ϩ stores needed for muscle excitation-contraction coupling. The differences in phenotypes with respect to humans could be due to the fact that ϳ40% of human diaphragm muscle fibers are slow-twitch type I, whereas in mice these fibers account for Ͻ10% of the total (231): the higher levels of SERCA2 in human diaphragm could thus explain the absence of respiratory failure in Brody's disease patients. Consistent with the role of the SERCA2a pump in heart, and of the SERCA2b pump as an ubiquitous pump, breeding of heterozygous null SERCA2 mutant mice yielded only wild-type and heterozygous offspring, which developed and grew with no apparent pathological phenotypes (5, 133, 142, 237, 268, 310) .
Numerous studies have shown that the reduction in SERCA2a activity or expression may contribute to the development of cardiac diseases; thus cardiac physiology studies were performed on heterozygous mutants, which exhibited a 65% reduction of the SERCA2a protein levels. Despite the development of compensatory mechanisms, i.e., upregulation of the Na ϩ /Ca 2ϩ exchanger and increased phosphorylation of PLB, the mutants had deficits in relaxation and contractility. Interestingly, the mean arterial blood pressure and the left ventricular systolic pressure were reduced under basal conditions and at lower levels of ␤-adrenergic stimulation, but not under conditions of maximal stimulation. Studies on isolated cardiac myocytes from heterozygous mice (142) have confirmed the deficit in contractility and have revealed reduced Ca 2ϩ transients induced by agonists. The reduction of SERCA pump levels reduced the size of the SR Ca 2ϩ store and the amount of Ca 2ϩ released at the beginning of each contractile cycle. However, even if the impairment of cardiac performance was clear, no evidence of heart failure or cardiac hypertrophy was observed (it was also not observed in Darier's disease patients, see above) showing that the loss of one copy of the gene was insufficient to trigger the heart defect (33, 288) . In another mouse model, the exon encoding the COOH terminus of SERCA2a was eliminated (310) so that the mouse expressed only the SERCA2b variant. The level of expression of SERCA2b in the hearts was ϳ60% of that of SERCA2a in wild-type hearts, and even if some embryonic lethality was observed, most of the homozygous mutants survived to adulthood and developed a compensatory cardiac hypertrophy (310), which was accompanied by a reduction in contractility and relaxation.
However, the most striking phenotype observed in SERCA2 heterozygous mutant mice in which the activity of the SERCA2 pump was reduced was a very high incidence of squamous cell tumors (187) , which occurred at 53 to 81 wk of age. The tumors were restricted to regions with keratinized, stratified epithelium and included carcinomas and papillomas of the oral mucosa, tongue, esophagus, forestomach, genitalia, and hairless areas of the skin. Darier's disease patients deficient in SERCA2 activity could be mentioned in this context: they do not exhibit strong propensity to cancer, but an association with squamous cell carcinoma may nevertheless exist (275) . Con-sidering the wide tissue distribution of the SERCA2b pump, it is surprising that no other clear pathological phenotype has emerged in mice lacking one copy of the gene. Evidently, an unusual compensation occurs, since in several tissues of SERCA2 heterozygous mutant mice the SERCA2 protein levels were only reduced by 20%. This suggests mechanisms for upregulating SERCA2 pump expression in response to a deficit in its level, or in its activity.
Null SERCA3 gene mutants exhibited no structural malformations and showed no apparent disease phenotype (188) , in agreement with the notion that the SERCA3 pump does not have a housekeeping function, as it is invariably coexpressed with the SERCA2b variant. SERCA3 pump is widely expressed in many tissues (198) . Considering that the expression of the SERCA3 pump is prominent in vascular endothelial cells (3, 322) and in pancreatic ␤-cells (8), smooth muscle relaxation and diabetes were investigated with particular attention. Smooth muscle relaxation defects were observed in SERCA3 null mutant mice in vitro; however, a corresponding in vivo phenotype was not observed. As for pancreatic ␤-cells, several missense mutations in the human SERCA3 gene have been associated with type II diabetes (306) , and reduced Ca 2ϩ -ATPase activity was found in a rat diabetes model (181) . Although alterations in Ca 2ϩ signaling have been found in null mutant ␤-cells, no defects in insulin secretion or glucose levels in the blood were detected, suggesting that the loss of SERCA3 activity did not cause diabetes, probably because of compensatory mechanisms that became activated.
B. The SPCA Pump

General properties
The Ca 2ϩ pump of the secretory pathway (SPCA) is the newest addition to the family of Ca 2ϩ -transporting ATPases. The first member of the subfamily (Pmr1, plasma membrane ATPase related pump) was identified in yeast (254) and was located in the Golgi membranes (4). The first mammalian member of the subfamily was cloned from rat in 1992 (116) . In humans the first SPCA pump (SPCA1) was identified less than 10 years ago in two studies that also described mutations leading to Hailey-Hailey disease (130, 283) . A second human SPCA pump (SPCA2) was described a few years later (304, 323) . One distinctive property of the SPCA pumps soon became evident: in addition to Ca 2ϩ , these pumps also efficiently transport Mn 2ϩ (302) . This peculiarity of the SPCA pumps is evidently related to the presence of a number of Mn 2ϩ -requiring enzymes in the lumen of the Golgi compartment, the most important being the glycosyltransferases. Among them, galactosyl transferases have been most extensively studied. N-acetyl-glucosamino transferases, mannosyl transferases, glucoronyl transferases, and fucosyl transferases are also Golgi enzymes that have Mn 2ϩ as a cofactor. The transport of Mn 2ϩ by the pump is also important for the regulation of the Mn 2ϩ concentration in the cytosol. Oxidative damage in yeast cells lacking SOD was suppressed in cells lacking functional Pmr1: they accumulated Mn 2ϩ , which replaces SOD as a scavenger of ROS in the cytoplasm (170) . However, Mn 2ϩ can also become toxic to cells. Since the SPCA pump is the major route for removing Mn 2ϩ from the cytoplasm, it has a major role in the process of Mn 2ϩ detoxification. Two isoforms of the SPCA pump have been described: SPCA1 is expressed ubiquitously and is thus considered a housekeeping enzyme. Its expression level varies with the cell type and is especially high in human epidermal keratinocytes (130) . The expression of SPCA2, instead, is more restricted. Transcript analysis has revealed high levels of expression of the SPCA2 pump in the mucus-secreting goblet cells of human colon (304) , suggesting a role for this pump in the secretion of mucus. Whereas tissue fractionation and immunofluorescence work has unambiguously located the SPCA1 pump in the Golgi compartment of mammalian cells (247, 301) , the subcellular localization of SPCA2 pump is less certain: in some cell types it colocalizes with Golgi markers (304); in others, e.g., hippocampal neurons, it colocalizes instead with trans-Golgi markers (323) . The SPCA1 is not the only pump that transports Ca 2ϩ into the lumen of the Golgi compartment. This was first indicated by the finding that the uptake of Ca 2ϩ into Golgi vesicles was partially inhibited by the SERCA pump inhibitor TG, which has very poor affinity for the SPCA pumps (5 orders of magnitude lower than for the SERCA pump). This has shown that a SERCA pump also contributes to the uptake of Ca 2ϩ in the Golgi compartment (289) . The contribution of the two pumps varies with the cell type, the SPCA pump taking primacy in human keratinocytes, where it contributes ϳ70% of the total Ca 2ϩ uptake into the Golgi vesicles (35) .
SPCA pumps are predicted to be organized in the membrane with 10 transmembrane helices and to protrude into the cytosol with a large headpiece, which is predicted to be divided in the three A, P, and N units identified in the SERCA pump (Fig. 7) . The sequence of SPCA pumps shares the critical consensus sites, e.g., the sequence (SDKTGTLT) surrounding the catalytic D residue with those of the SERCA pump (and of the PMCA pump, see below). SPCAs are shorter than the SERCA pumps (and, especially, than the PMCA pumps, see below): this is due to the shorter luminal loops that connect some of the transmembrane domains, and to the absence of a long cytoplasmic tail. The NH 2 -terminal domain of human SPCA2 is 32 residues longer than that of human SPCA1 (323) : it may be involved in specific interactions with partner proteins and in domain rearrangements that could modulate the affinities for the transported ions, in analogy with what proposed for the copper transporting ATPase (134) . SPCA2 also diverges substantially from SPCA1 in the COOH-terminal portion. A putative retrieval motif from the plasma membrane (L925L) (323) and a COOH-terminal PDZ binding motif (P943EDV) have been identified (125, 315) , which could be involved in the intracellular trafficking and location of the SPCA2 pump (110) . A EF-hand Ca 2ϩ binding motif has been identified in the NH 2 -terminal domain of the yeast Golgi Pmr1. It could be involved in the regulation of the transport function of the pump (317), much as the COOH-terminal Ca 2ϩ binding sites that have been identified in the PMCA pump would do (128) (see below). Sequence comparison with the SERCA pump predicts that the SPCA pump only has one Ca 2ϩ transport site, corresponding to SERCA site II, consistent with a probable 1:1 Ca 2ϩ /ATP transport stoichiometry. The site appears to be formed by oxygens of residue E329 in transmembrane domain 4 and N796 and D800 in transmembrane domain 6 (316) . Work on the Pmr1 yeast enzyme (196, 197) has shown that the Mn 2ϩ selectivity of the pump is instead defined by residue Q783 in transmembrane domain 6, and by conformation-sensitive packing interactions between Q783 and V335 in transmembrane domain 4. However, G309 could also be involved in the conferral of Mn 2ϩ binding selectivity at the cytosolic side (86) .
The SPCAs are sensitive to the general P-type pump inhibitors La 3ϩ and orthovanadate and only very poorly sensitive to the specific SERCA pump TG. The other two commonly used specific SERCA pump inhibitors (CPA and tBHQ) are nearly ineffective (204) . The very poor sensitivity to thapsigargin is consistent with the absence of the F residue equivalent to F256, which is essential for the binding of TG in the SERCA pump (see above). No specific SPCA inhibitors have so far been described, and endogenous activators are also unknown.
The two SPCA pumps have higher affinity for Ca 2ϩ than the two other Ca 2ϩ pumps: the K d (Ca 2ϩ ) of SPCA1 is ϳ10 nM (69) and is ϳ2.5 times lower in SPCA2 (70): the higher Ca 2ϩ affinity of the SPCAs with respect to the two other Ca 2ϩ pumps has been related to a slower E1-P(Ca 2ϩ )/E2P transition in the reaction cycle (69). The extremely high Ca 2ϩ affinity of the SPCA pumps, which have a K d for Ca 2ϩ below its presumed concentration in most cytosols at rest, ensures that the Golgi compartment will be constantly refilled with Ca 2ϩ , which is evidently needed inside the vesicles for the optimal activity of a number of important enzymes, most notably the endoproteases that perform the proteolytic processing of prohormones (50, 219) , even in the absence of agonist-induced cytosolic Ca 2ϩ transients. As in the ER Ca 2ϩ store, a large fraction of the Ca 2ϩ in the Golgi lumen is sequestered by binding proteins. Some of those typical of the ER lumen have also been detected in the Golgi compartment (31, 314) , but others appear to be restricted to it, e.g., nucleobindin (184) and Cab45 (261) .
At variance with the SERCA and PMCA pumps (see below) which function as partially electrogenic H ϩ exchangers (however, see below for very recent findings on the PMCA pump), the SPCA pumps do not appear to countertransport H ϩ . Protons are needed for a number of important functions in the lumen of the Golgi vesicles and must thus be kept inside. Both SPCAs transport Mn 2ϩ with an affinity that is as high as that for Ca 2ϩ . As mentioned, the transport of Mn 2ϩ is demanded by the needs of Mn 2ϩ requiring N-and O-linked glycosylations of a number of proteins (150, 308) which occur inside the Golgi compartment. It is also required for optimal activity of a Golgi-located casein kinase (171, 318) .
Alternative splicing only occurs in the primary transcripts of SPCA1. The primary transcript of SPCA2, instead, is not known to undergo alternative splicing, i.e., only one SPCA2 isoform (946 amino acids) is known. In the SPCA1 pump, alternative splicing at the 3Ј-end of the primary mRNA results in the generation of four transcripts resulting from the coupling of exon 26 to exon 27, which contains two internal splice donor sites, or to exon 28, one transcript containing exon 28 and the portion of exon 27 up to one donor site, the other exon 28 and the portion of exon 27 up to the second donor site. The resulting four isoforms (SPCA1 a-d) have COOH-terminal domains of different length and sequence (Fig. 8) (300) . Information on possible differential properties of SPCA1 isoforms is still very scarce, although some kinetic differences have been detected. 
The Hailey-Hailey's disease
In 1939 two dermatologist brothers described a familial benign chronic pemphigus, a skin disorder that was eventually named after them (117) . The disorder affects both sexes and is inherited in an autosomal dominant way, with symptoms typically arising in the third or fourth decade of life. The disease has similarities to Darier's disease. It also presents with blisters and itchy erosions mainly located at sites of sweating and friction like the groin and the axillar regions, with pain and unpleasant smell of the skin following the development of macerations. The disease proceeds through remissions and exacerbations caused by a number of external factors like friction, sweating, infections, and ultraviolet exposure. In 2000, inactivating mutations in the disease were discovered in one allele of the gene coding for SPCA1 (ATP2C1) (130, 283) . The disease is essentially benign, but squamous cell carcinomas may develop from the skin lesions. This point is important, as the disruption of SPCA1's gene in mice instead causes a number of squamous cell carcinomas, but not the acantholytic skin disorder (225) it causes in humans. It has thus been proposed that a prosurvival response would predominate in the Golgi (but also in the ER) of mice keratinocytes, leading to cancer, whereas proapoptotic responses would predominate in the Golgi and ER of keratinocytes in humans leading to the acantholytic skin disorder (225) . Interestingly, the SPCA may be involved in breast cancer as well: SPCA2 may have a role in the normal functioning of the mammary gland, as a pronounced increase in the SPCA2 mRNA levels was detected in the gland during lactation, in analogy to what was found for isoform 2 of the PMCA pump (85) (see below). A similar increase has also been found in breast cancer.
Histologically, Hailey-Hailey's disease is characterized by the loss of adhesion between suprabasal keratinocytes (acantholysis) and by the abnormal keratinization of the epidermis (dyskeratosis) (Fig. 9) . Aggregates of keratin filaments in the perinuclear region of keratinocytes are a distinctive feature (120, 122, 201) . Following the first description of the defect in the SPCA gene, ϳ100 additional mutations were identified, randomly scattered in the gene (300) . The mutations downregulate the expression of the SPCA1 pump in the keratinocytes (17, 240) , a finding that has been confirmed by expressing mutated versions of the SPCA1d pump in model cells (86, 87) : about half of the mutations produced low levels of SPCA expression (the amount of transcript, however, was normal). In addition to the downregulation, a number of mutants displayed instead deficient binding of Ca 2ϩ and of Mn 2ϩ to the pump, or a dysfunction in the E1-P(Ca 2ϩ ) to E2-P conformational transition in the reaction cycle. The molecular link between the impaired expression and/or the functional defect of SPCA1 and the skin lesions is still not understood. Since the SPCA pump also transports Mn 2ϩ , it would in principle be possible to relate the disease to a defect in the transport of Mn 2ϩ . However, the close similarity between Hailey-Hailey's and Darier's diseases convincingly indicates that the inability of the SPCA pump to efficiently transport Ca 2ϩ is the causative factor in the disease (the SERCA2 pump has essentially no Mn 2ϩ transport ability). The Ca 2ϩ transport defect is expected to decrease Ca 2ϩ in the Golgi lumen of keratinocytes, as the defect of the SERCA pump decreased it in the ER of Darier keratinocytes, thus impairing the posttranslational processing and targeting of proteins which are essential for the biogenesis of the cell adhesion structures. A molecular pathogenesis of the skin defect similar to that of Darier's disease could be envisaged in the Hailey-Hailey's disease; however, the picture is likely to be more complex and not limited to processes taking place in the Golgi lumen: an increase of basal cytosolic Ca 2ϩ has also been reported in Hailey-Hailey keratinocytes (130), which would be compatible with cytosolic Ca 2ϩ signaling defects. Others (179), however, have not confirmed the cytosolic Ca 2ϩ increase in cultured keratinocytes, but have reported a decrease in the amount of Ca 2ϩ released by TG and a reduced response of cytosolic Ca 2ϩ to the stimulation of purinergic receptors. An important factor to be considered in the molecular pathogenesis of HaileyHailey's disease (possibly, of Darier's disease as well) is the disruption of the Ca 2ϩ gradient: in the layers of normal epidermis, Ca 2ϩ is lowest in the basal layer and highest in the granular layer (82, 199) . It is generally accepted that the gradient is due essentially to extracellular Ca 2ϩ , which is necessary for the assembly of desmosomes and adherent junctions in the suprabasal layers of the epidermis. The concentration of extracellular Ca 2ϩ in the basal layer where proliferation occurs is actually lower than in most other extracellular fluids. Increases of external Ca 2ϩ in the latter layer above 0.1 mM activate the Ca 2ϩ sensing receptor (21) that is present in the plasma membrane of keratinocytes, blocking their proliferation and triggering instead their differentiation. The differentiated keratinocytes would then move upwards in the epidermis, eventually ending up in the cornified layer. No Ca 2ϩ gradient has instead been found in the skin of Hailey-Hailey's disease patients, even in nonaffected areas (17, 130) , i.e., the basal and suprabasal layers of the epidermis contain the same low amount of Ca 2ϩ . According to an attractive proposal (153) , the disruption of the Ca 2ϩ gradient would be crucial to the molecular etiology of Hailey-Hailey's disease: in normal skin, insults that disrupt the skin permeability barrier upon wounding eliminate the Ca 2ϩ gradient. The resulting increase of Ca 2ϩ in the extracellular space of the more profound layers of the epidermis directly stabilizes the desmosomes. However, it would also activate the plasma membrane Ca 2ϩ sensing receptor to trigger cell-to-cell adhesion and differentiation of the cells in the granular layer, repairing the wound and reconstituting the Ca 2ϩ gradient. In the Hailey-Hailey skin, instead, noxious stimuli would somehow fail to increase extracellular Ca 2ϩ in the suprabasal (granular) layers of the epidermis, failing to stabilize desmosome integrity and to activate the Ca 2ϩ -sensing receptor. It still remains to be understood, however, how the SPCA pump defect would mechanistically exacerbate the cell adhesion problem. The defects in the posttranslational processing of proteins that will eventually contribute to the formation of desmosomes which has been described in Darier's disease (see above) could possibly have a role in the Hailey-Hailey's disease. Other observations that could be relevant to the problem deserve to be mentioned here even if their involvement in the molecular etiology of the disease is at the moment purely speculative: for instance, the finding that the Ca 2ϩ -sensing receptor would be also expressed in the Golgi network (298) and the discovery that one of the Trp channels (TrpV6) is an important Ca 2ϩ influx path in keratinocytes (175) . As for the rise in extracellular Ca 2ϩ , which would be reflected in the increase of cytosolic Ca 2ϩ , it could lead to the translocation to the nucleus of transcription factors that would activate the SPCA gene (151, 200) . Others, however, have found no changes, or even a decrease, in SPCA1 pump expression when extracellular Ca 2ϩ was increased (245, 326) . Eventually, the SPCA defect must be causatively related to the inability of keratinocytes to increase external Ca 2ϩ in the granular layer: this could be possibly linked to the special functional properties of the SPCA pump, which are different from those of the SERCA and PMCA pumps, and which are evidently uniquely qualified to maintain the proper function of keratinocytes (including their ability to build the epidermal Ca 2ϩ gradient). It is interesting that Darier's disease, which causes an apparently very similar keratinocytic defect, is instead related to mutations in the SERCA pump. Long-term transcriptional effects are also likely to be important, but the finding that the HaileyHailey rash that follows physical trauma develops very rapidly is difficult to reconcile with transcriptional effects, and with other relatively slow processes.
C. The PMCA Pump
General properties
The PMCA pump was discovered in 1966 by Schatzmann (260) as an ATP-driven system that expelled Ca 2ϩ from erythrocytes. Initially, most of the work concentrated on erythrocytes, but then spread gradually to other cells, including those of excitable tissues, where a larger Ca 2ϩ extrusion system, the Na ϩ /Ca 2ϩ exchanger, predominates quantitatively. The pump was isolated and purified in 1979 using a calmodulin column (214) that exploited the finding (106, 140) that the pump was a target of calmodulin regulation. It belongs to the PIIB subfamily of P-type pumps. The pump operates with high Ca 2ϩ affinity and low transport capacity, with a 1:1 Ca 2ϩ /ATP stoichiometry. It operates as a Ca 2ϩ /H ϩ exchanger, but the matter of Ca 2ϩ /H ϩ stoichiometry is still controversial. Work on the purified pump reconstituted in liposomes had indicated electroneutrality (215), whereas other experiments had instead indicated a partially electrogenic 1:1 Ca 2ϩ :H ϩ transport process (119) . Very recently, the activity of the pump in native membranes has been found to be insensitive to the variation of the membrane potential, indicating an electroneutral H ϩ /Ca 2ϩ reaction (291) . Under optimal conditions, the K d of the pump for Ca 2ϩ drops from the 10 -30 M range in the pump at rest to the 0.2-0.5 M range routinely measured under optimally activated conditions. Even under optimal conditions the Ca 2ϩ affinity of the PMCA pump is thus lower than that of the SPCA pumps, but is high enough to enable it to operate with reasonable efficiency even under the Ca 2ϩ concentration conditions prevailing in most cytoplasms at rest; accordingly, the PMCA pump is conventionally defined as the fine tuner of cytosolic Ca 2ϩ . As all P-type pumps, the PMCA pump is inhibited by La 3ϩ and vanadate. No really specific inhibitor comparable to TG exists, even if carboxyeosin is frequently mentioned (98) . More recently, however, synthetic peptides of the caloxin family have been claimed to specifically inhibit the PMCA pump (285) . Interestingly, caloxin peptides, of which several have now been tested, bind to the extracellular domains of the pump (129) and could thus in principle be used to inhibit the PMCA pump in intact cell systems. They have also been claimed to have isoform-specific inhibitory properties: one of them (caloxin 1C2) has strong preference for PMCA isoform 4 (K i ϭ 2.35 M, compared with 10 times higher K i values for PMCA1, -2, and -3) (232).
The PMCA pump was cloned in 1988 (276, 313) , showing the same essential membrane organization and topology properties of the SERCA pump, which were already known at the time of the cloning. The 3D structure of the pump has not yet been solved, but molecular modeling work based on the structure of the SERCA pump predicts the same general features, with 10 transmembrane domains and the large cytosolic headpiece divided into the three main A, N, and P domains (Fig. 10) . As expected, the catalytic phosphorylation site (SDKT-GLT) is conserved as are other important consensus domains, but prominent sequence/domain differences with respect to the other two Ca 2ϩ pumps also exist, for instance, in the first cytosolic loop that contains an acidic phospholipid binding domain (see below), and, especially in the long cytosolic COOH-terminal tail, which is absent in the SERCA and SPCA pumps. The comparison with the sequence of the SERCA pump also reveals important differences in the amino acids that contribute to the formation of the Ca 2ϩ binding sites. As already mentioned, one essential acidic residue (an E) that contributes coordinating oxygens to site 1 of the SERCA pump is missing in transmembrane domain 5 of the PMCA pump, which thus does not have site 1. As in the case for site 2 of the SERCA pump, the residues that coordinate Ca 2ϩ in the single PMCA site are part of transmembrane domains 4 and 6 (115) . Interestingly, the insertion of the missing acidic residue in transmembrane 5 of the PMCA pump by a mutagenesis approach raised its Ca 2ϩ /ATP stoichiometry to 2, suggesting the formation of a second Ca 2ϩ binding site which corresponds to site 1 of the SERCA pump (115) . The long COOH-terminal tail of the PMCA pump contains most of the regulatory domains, the most prominent among them being the calmodulin binding domain, which has the canonical amphipathic helix secondary structure of calmodulin binding domains (138) . Ca Under nonactivated conditions, the COOH-terminal tail of the pump is proposed to fold over to interact with two sites in the first and second cytosolic loops of the enzyme, compromising the access to the active site (88, 89) . Calmodulin then interacts with its binding domain, removing it from its docking sites next to the active center, freeing the pump from autoinhibition. At variance with all other targets of calmodulin regulation, the PMCA pump can be activated by the COOH-terminal half of calmodulin isolated after trypsin cleavage (113) . This is in line with the 3D structure of the complex of calmodulin with a synthetic peptide corresponding to the main portion of the PMCA calmodulin binding domain, which has shown that the PMCA only interacts with the COOHterminal portion of calmodulin (83) . One important distinctive property of the PMCA pump is the multiplicity of activatory mechanisms. Next to calmodulin, the most in- teresting activators are acidic phospholipids (213) , which bind to two sites in the pump molecule: one is the calmodulin binding domain (28) , and the other (see above) is a stretch of ϳ40 predominantly basic amino acids in the cytosolic loop that connects transmembrane domains 2 and 3 (330) : which of the two sites is more important as a mediator of the response to acidic phospholipids is still not known. The activation by acidic phospholipids is likely to be physiologically important, as they are present in the membrane environment of the pump: it has been calculated that the concentration of phosphatidylserine in the environment of the erythrocyte membrane that surrounds the pump would be sufficient to permanently stimulate the pump to ϳ50% of maximal activity (212) . Since the most effective acidic phospholipid is the doubly phosphorylated derivative of phosphatidylinositol (PIP 2 ), the concentration of which becomes modulated in the membrane during Ca 2ϩ related signaling processes, a possible PIP 2 -mediated reversible cycle of PMCA activation could be envisaged (55) . Other activatory mechanisms of the pump are phosphorylations by protein kinase C and protein kinase A (the latter only in one of the isoforms), an oligomerization (polymerization) process involving the calmodulin binding sequence in the COOH-terminal tail of the pump, and the cleavage by calpain. As no conclusive information is available on the physiological relevance of these mechanisms, they will not be discussed here. They are, however, discussed in detail in a number of reviews (e.g., Refs. 43, 112). However, the cleavage by calpain will be briefly mentioned. It occurs immediately upstream of the COOH-terminal calmodulin binding domain (139) and activates the pump irreversibly, making it calmodulin insensitive. This irreversible mechanism of activation could become significant in conditions of pathological Ca 2ϩ overload that would demand increased Ca 2ϩ exporting ability (258) .
The cloning of the pump was soon followed by a number of studies that showed that in mammals the enzyme was the product of a multigene family (ATP2B1-4). Four basic gene products were soon discovered, the transcript of each undergoing a complex alternative splicing process that increases the total number of presently recognized isoforms to ϳ30 (see Refs. 112, 230, 280 for comprehensive reviews of this aspect of the PMCA pump). The four gene products (PMCA pump isoforms 1-4) differ in tissue distribution and calmodulin affinity ( Table 1) . Pumps 1 and 4 are ubiquitous and have poor calmodulin affinity, and pumps 2 and 3 have higher calmodulin sensitivity and their expression is restricted to some tissues: PMCA2 is expressed prominently in the nervous system and in the mammary gland and PMCA3 in the nervous system (280). These are not the only distinguishing properties of the isoforms; for instance, Table 1 shows that PMCA1 has peculiar calpain sensitivity: additional differences have also been discovered in the interaction of the isoforms with protein partners (see below). The isoform work has gradually made clear that the PMCA2 pump has properties that single it out from the other three basic isoforms. For instance, it has peculiarly high resting activity so that calmodulin, which normally stimulates the activity of the other three pumps four-to sixfold, only increases its activity by 20 or 30% (Table 2 ) (84, 126) . This peculiarity of PMCA2, as well as others to be discussed below, could explain its predominance in cells that have special Ca 2ϩ homeostasis demands. Alternative splicing occurs in the transcripts of all four pump isoforms. It occurs at two sites that do not involve, as expected, the catalytic core of the ATPase. Site A is located upstream of the phospholipid binding domain in the first cytosolic loop of the pump, and site C inside the calmodulin binding domain in the COOH-terminal tail (Fig. 11) . Two nomenclature systems have been proposed to identify the splice variants (37, 152) . In the most commonly used, site A inserts are designated with letters from z to w according to the number of the exons inserted. The splicing operation at this site shows once more the peculiarity and special complexity of PMCA2: three exons may The notation 1-4b refers to the full-length pump, without splicing inserts (see text). The information given in Table 1 , for instance, calmodulin (CaM) affinities, has been extracted from several of the articles quoted in the text. CALCIUM PUMP DYSFUNCTIONS be alternatively inserted in its primary transcript leading to variants w (three exons of 33, 60, and 42 bp), y (two exons of 33 and 60 bp), and x (one exon of 42 bp). Variant y, however, has so far been only identified in rats, and a variant v, in which a fourth novel exon is transcribed at site A, has been found in the bullfrog (76) The variant of PMCA2 in which no extra exons are included at site A is designated with the letter z. Variant z is not found in PMCA1, as all mature transcripts of this isoform invariably contain a 39-bp exon, which in all other isoforms is only alternatively included, leading to variant x. Thus all PMCA1s known correspond to the x variant. PMCA3 and PMCA4 exist in two variants: z (no extra exons in the transcripts) and x (two exons of 42 and 36 bp, respectively). The splicing process at site C is characterized by splice sites internal to exons, read-through across adjoining exons, and inclusion of full extra exons. As a result, in the multitude of variants that are generated, changes in reading frame occur that lead to the creation of premature stop codons, and to the truncation of the resulting proteins. Pumps in which no insertions occur at site C are designated as b variants. As a rule, a single exon is inserted at site C in the transcripts of PMCA1 (154 bp) and PMCA4 (175 bp), but the insertion occurs piecemeal, leading to variants c, d, e, and a (full exon transcribed) in PMCA1, and to variants d and a (full exon transcribed) in PMCA4. The insertion of the 154-bp exon, or of portions of it, in the transcript of PMCA3 leads to variants a (full exon included) or c and d. Variants e and f have also been described. In the former, 88 bp of the following intron and a poly(A) tail were added to the 154-bp exon. In the latter, a 68-bp exon, located upstream the 154-bp exon, was included. In the case of PMCA2, two, and not only one, novel exons (172 and 55 bp, respectively) can be included or excluded. The resulting variants are designated as c or a (both exons inserted). Again, the splicing at site C shows the peculiar complexity of PMCA2. The multitude of PMCA isoforms, especially of those generated by alternative splicing of the transcripts, is not easily rationalized in terms of function. The four basic isoforms have all been purified and characterized (even if the most important information on the isolated enzyme has been obtained on purified PMCA4), but only scarce information is available on the differential activity of splice variants. It is known, however, that the insertion of the three exons at site A (which corresponds to a 45-residue insertion, the w form) directs PMCA2 to the apical domain of polarized cells, whereas smaller inserts sort the protein to the basolateral domain of the plasma membrane (53) . It is also known that the COOH-terminal truncation determined by the C inserts (the a variants) lowers, as should be expected, the affinity of the truncated pumps for calmodulin (27, 242) .
One interesting property of the PMCA pump that is related to the multiplicity of its isoforms is its inhomoge- neous distribution in the plasma membrane: in a number of cell types, the pump has been shown to be associated with the caveolae (96), a functionally convenient location, as caveolae, at least in some cell types (e.g., intestinal smooth muscle), are in close contact with the ER (239) and would thus facilitate the extrusion of Ca 2ϩ liberated by it. In addition to caveolae, the cholesterol-rich lipid rafts, which are emerging as important domains in cell signaling, also appear to be loci for specific association with the PMCA. Recent studies on cerebellar synaptosomal plasma membranes (273) have shown that one PMCA isoform, PMCA4, is specifically associated with the lipid rafts, whereas the other PMCA isoforms are not. The specific association of PMCA with caveolae/lipid rafts has been confirmed in a recent study on intestinal smooth muscle (81) . The results of the study have indicated that one splice variant of isoform 4 of the pump (PMCA4b) could specifically associate with caveolin 1, whereas another splice variant (PMCA4a) could be instead associated with lipid rafts.
One important development that may rationalize the existence of so many PMCA pump isoforms, including the splice variants, is the identification of protein partners that regulate activity, targeting to membrane domains, and/or the recruiting of pump variants to cell components (e.g., the cytoskeleton). This area of work has now grown significantly, but only some of the information that has been generated has so far considered differences among isoforms. A large number of proteins interact with a PDZbinding domain in the COOH-terminal tail of the pumps. Among them are members of the MAGUK (membrane associated guanylate kinases, or SAP) family of protein kinases which contain PDZ domains and are associated with the cortical actin cytoskeleton (63) . The pump variants studied have been the 2b and 4b: it has been suggested that the interaction could maintain the pumps in specific membrane domains to control local Ca 2ϩ homeostasis. Along similar lines of work, PMCA 4b has been shown to redistribute to newly formed platelet filopodia via the PDZ binding domain (61) . CASK (Ca 2ϩ -calmodulin dependent serine protein kinase) is another MAGUK protein that interacts with PMCA4b (266) . It is a coactivator of the transcription of T-element containing promoters and has been suggested to downregulate the T-elementdependent reporter activity by depleting Ca 2ϩ in the immediate environment of the enzyme: the suggestion has been made that the interaction of the pump with CASK could have a role in the regulation of synaptic activity, as CASK is located at brain synapses. Another PDZ domaincontaining protein, NHERF2 (Na ϩ /H ϩ exchanger regulatory factor 2), has been shown to interact with PMCA2b, but not with PMCA4b (62): it could provide a scaffolding mechanism to bring together membrane proteins, signaling molecules, and the cytoskeleton. The PDZ binding domain also directs the interaction of PMCA 4b with nitric oxide synthase 1 (NOS-1) in a ternary complex with ␣-syntropin in which the latter binds to a pump domain further upstream in the sequence (320) . The double interaction thus downregulates the production of NO by decreasing Ca 2ϩ in the immediate vicinity of the synthase; therefore, the pump could function as a modulator of signal transduction, in addition to regulating cell Ca 2ϩ (46) . Other proteins containing PDZ domains that interact with PMCAs are the following: PISP (PMCA interacting single PDZ domain protein), which could have a role in the sorting of the pump to the plasma membrane (102); Ania-3, a member of the Homer family of scaffolding proteins that couple NMDA and metabotropic glutamate receptors (274) , and could recruit PMCAs to domains close to Ca 2ϩ influx channels to control neuronal Ca 2ϩ signaling and synaptic function; CLP36, a member of the LIM family of proteins that interacts with the platelet cytoskeleton via its constitutive association with the actin binding protein ␣-actinin (25) . The association with PMCA 4b would recruit the pump to nonfilamentous actin complexes in resting platelets, and then associate it with the actin cytoskeleton during its rearrangement upon platelet activation. In addition to the COOH-terminal domain, other regions of the pumps also interact with protein partners. The main intracellular loop joining transmembrane domains 4 and 5 binds RASSF1 (tumor suppressor RASassociated factor 1), inhibiting the epidermal growth factor-mediated activation of the RAS signaling pathway (7). The main intracellular loop also interacts with ␣-syntropin (see above), and with the catalytic subunit of calcineurin. Since the pump does not interact with the consensus sequence for calcineurin anchoring proteins (32), a novel type of interaction could operate. The interaction would downregulate calcineurin activity, thus acting as a negative modulator of calcineurin signaling pathways. The NH 2 -terminal cytosolic region of the pump has a low degree of sequence homology among isoforms and has thus been exploited in a search for isoform specificity in interacting partners. The study has identified protein 14.3.3 and has further underlined the uniqueness of PMCA2 among isoforms, as protein 14.3.3 (the -isoform) interacted with PMCA1, -3, and -4, but not with PMCA2 (185, 250) . The study has also shown that the interaction with protein 14 -3-3 inhibited pump activity.
The PMCA pump in the disease process
Several mammalian genetic and nongenetic pathologies linked to dysfunctions of the PMCA pump have been described, with those of genetic origin being the best characterized. A number of disease conditions linked to the ablation, or to partial disruptions, including point mutations, of the genes for the PMCAs, have been described in mice, but the only spontaneous human disease related to a PMCA pump defect so far identified is a form of hereditary deafness (91, 269) . The defect concerns the PMCA2 pump, which is abundantly expressed in the brain, particularly in the Purkinje cell of the cerebellum and in the hair cells of the Corti organ of the inner ear, where it locates specifically to the stereocilia (Fig. 12) . That the PMCA2 pump was involved in the hearing process had become clear from the analysis of the phenotype of the PMCA2 knockout mice (162) , which was characterized by balance impairment and hearing loss. The study of the vestibular inner ear revealed the absence of the otoconia and the progressive degeneration of the hair cells beginning 10 days after birth. The PMCA2 pump is probably also essential in neuronal Ca 2ϩ homeostasis, since PMCA2 null mice and a defective mutant mouse (deafwaddler mouse, see below) showed a significant reduction in the number of spinal cord motor neurons (168) and abnormalities in Purkinje neurons (167) . However, the balance defect was apparently not due, or was only partially due, as could have been expected, to a cerebellar dysfunction, but was apparently related to the absence of the calcium carbonate crystals of the otoconia embedded in the otolithic membrane overlying the sensory epithelium that sense gravity and linear acceleration in the inner ear.
At about the time of the generation of the PMCA2 knockout mice, the first spontaneous mutation of the PMCA2 pump was described in the deafwaddler mouse (279) , which carried either a point mutation in the first cytosolic loop of the pump (G283S), or a frame shift mutation in codon 471 of the gene, generating a null mutant. The mutants had equilibrium problems and severe hearing impairment. Soon afterwards, another spontaneous PMCA2 mutation that produced hearing loss and equilibrium imbalance was described in the Wriggle Sagami mouse (287) . In this case a replacement (K412E) occurred in the fourth transmembrane domain of the pump, preventing its targeting to the stereocilia. The mistargeting of the pump in the outer hair cells of the Wriggle Sagami mouse was to be expected, as it is generally assumed that mutations in the transmembrane domains of the pump prevent its correct delivery to the plasma membrane (115) . Thus the recent finding that another deafness-inducing point mutation (S877F) in the sixth transmembrane domain of mice PMCA2 (278) still permitted its correct delivery to the plasma membrane was surprising.
Two deafness-inducing PMCA2 mutations described in humans (91, 269) have extended the information provided by the mouse models. In both cases, the mutation of PMCA2 required a concurrent mutation in cadherin 23 to generate, or to exacerbate, the hearing loss phenotype. Cadherins are a family of plasma membrane receptors that mediate Ca 2ϩ -dependent cell-cell adhesion and play a key role in the regulation of organ and tissue development during embryogenesis. Cadherin 23 is a component of the tip-links in the stereocilia of the hair cells and participates in the mechanoelectrical transduction process, i.e., in the conversion of mechanical force into electrochemical signals. In the family described by Schultz et al. (269) , a substitution (V586M) in the sequence of the pump that defines the ATP binding site enhanced the auditory defect in three out of five siblings who also had an accompanying mutation in the gene of cadherin 23. The PMCA2 mutation (G293S) in the family described by Ficarella et al. (91) had a number of additional aspects of interest. It clearly defined a digenic mechanism for the hearing loss phenotype, as the affected child carried both the mutation in the PMCA2 gene and a concomitant mutation in cadherin 23 (different from that described by Schultz et al.) . However, the father of the child had the cadherin 23 mutation and had no hearing loss phenotype, and the mother, who had the PMCA2 mutation, was equally healthy. The G293S mutation, which still permitted the regular targeting of the pump to the stereocilia, was located only 10 residues downstream of that of the deafwaddler mice and involved the same two amino acids. Evidently, the cytosolic loop where the deafwaddler and the human mutations occurred, even if distant from the active site and apparently not involved in any of the known important functions of the pump, is a functionally sensitive region. The study by Ficarella et al. (91) also analyzed molecularly the defect of the pump; as mentioned above, the PMCA2 pump has uniquely high activity in the absence of the activator calmodulin and reacts poorly to it, i.e., it appears to be programmed to continuously pump Ca 2ϩ out of the cells where it resides with reasonable efficiency irrespective of whether calmodulin and presumably other putative activators act on it. This is at variance with the other three basic isoforms of the pump, which only pump Ca 2ϩ efficiently when activated by calmodulin (or, possibly, by other factors). Importantly, the variant of the PMCA2 pump present in the stereocilia is not the full-length z/b, but the w/a variant (107) which contains the A site insert specified by the three extra exons that direct it to the apical pole of the cell. It is also COOH-terminally truncated and would thus be expected to have even lower calmodulin reactivity than the conventional z/b variant of the PMCA2 pump that reacts poorly to calmodulin, as it has lost about half of the calmodulin binding domain. Thus it would eject Ca 2ϩ continuously but would be expected to respond even more poorly than the full-length PMCA2 pump to the sudden arrival of a Ca 2ϩ bolus. The comparison of the Ca 2ϩ ejecting properties of the z/b and w/a PMCA2 pump variants shown in Figure 13A indeed shows that the two pump types expressed in model cells behaved as expected, i.e., the variant resident in the stereocilia was much less able to control the Ca 2ϩ transient induced by the stimulation of the cells with a suitable agonist than the full-length z/b variant. Figure 13A is particularly informative as it describes an experiment performed in the native intracellular environment. Evidently, the special properties of the PMCA2 pump satisfy the peculiar Ca 2ϩ homeostasis demands of hair cells, in which the role of the pump is to eject Ca 2ϩ from the stereocilia to the endolymph with an efficiency poised to maintain the free Ca 2ϩ concentration in it which is much lower than in all other conventional extracellular spaces (ϳ20 M, Ref. 321). The reasons for the unusually low free Ca 2ϩ concentration of the endolymph are likely to be related to the physiology of the tip links and of the gating of the mechanoelectrical transduction channels that are opened by the displacement of the stereocilia bundle to permit influx of K ϩ (and Ca 2ϩ ) into the stereocilia. They may also be related to other special regulatory demands of the stereocilia/endolymph system. Figure 13B shows that the mutant G293S pump, and the deafwaddler G283S mutant shown for comparison, did not differ from the wild-type w/a pump in the poor ability to control the Ca 2ϩ pulse, but were peculiarly inefficient in the long-term, nonactivated pumping of Ca 2ϩ out of the model cell used for the analysis. It is plausible to assume that they would act in the same way in the real inner ear situation, in which they are requested to pump Ca 2ϩ out of the stereocilia to the endolymph. Experiments on organotypic cochlea and utricula cultures have indeed shown that this is the case (91) . The lowering of Ca 2ϩ near the tip links linked to the dysfunction of the pump could increase the opening probability and unitary conductance of the mechanoelectrotransduction (MET) channels, eventually depolarizing the hair cells, and compromising the generation of the hearing signals (Fig. 14) .
In addition to the inner ear, PMCA2 is also prominently expressed in other brain regions, and its dysfunction may have a role in some typical neurodegenerative diseases: a transcriptional downregulation of PMCA2 has for instance been described in the brains of mouse models of Huntington's disease and in the brains of Huntington's disease patients (164) . The dysfunction may contribute to the alteration of the homeostasis of Ca 2ϩ which is widely considered to have a role in the etiology of the disease. PMCA2 is also prominently expressed in the epithelial cells of the mammary gland and has an important role in the regulation of the concentration of Ca 2ϩ in the milk. Mammary gland epithelial cells need to continuously and efficiently eject Ca 2ϩ to supply it to the milk during lactation, and this is probably why they express the w/b splice variant, which contains the A splice insert that directs it to the apical pole of the cell, where it would continuously eject Ca 2ϩ to the milk. In keeping with the special properties of PMCA2, it would do it irrespective of the effect of activators like calmodulin. To respond to the demands of lactation, the w/b variant becomes highly expressed during lactation (246) .
Very recently, a missense mutation of PMCA3 gene which causes a T543M substitution was identified in human pancreatic cancer cells (145) . Interestingly, the mutation was located between the catalytic D residue and the K which is a component of the ATP-binding site, and affected a residue located in one of the two docking site for the calmodulin binding domain. No indications have been offered for a role of the PMCA3 in pancreatic tumorigenesis, but it is interesting that the PMCA3 pump has been identified in pancreatic islet cells (147) .
Genetic manipulations of the PMCA pumps
The PMCA2 knockout mice have already been mentioned. The ablation of the PMCA2 gene, in addition to generating the hearing loss phenotype discussed above, also strongly reduced the concentration of Ca 2ϩ in the milk (248) . Knockout mice have also been developed and the phenotypes studied for PMCA1 and PMCA4, but not yet for PMCA3. This isoform is widely expressed in developing embryos and may thus be essential for normal gestation.
The ablation of the PMCA1 gene has resulted in early embryonic lethality in homozygotes, underlying the essential role of PMCA1 in the early stages of development and in organogenesis, in line with the suggested housekeeping function of this isoform (226) . Heterozygotes, in contrast, appeared healthy; however, loss of one copy of the PMCA1 gene in mice with a PMCA4 null background led to increased propensity to apoptosis in the smooth muscles of blood vessels, possibly due to Ca 2ϩ overload (226) . The ablation of the PMCA4 gene did not cause a very evident general pathological phenotype (264) , but local defects were present. This is interesting, as PMCA4 is also very widely expressed and has also been proposed to play a housekeeping role. However, it has now become evident that PMCA4 plays more specialized roles as well and is not essential for the general function of controlling Ca 2ϩ homeostasis in all cells, although it contributes to it. One prominent observed defect caused by PMCA4 dysfunction was male infertility, which reflected the dominance of the PMCA4 pump in the testis, where it represents Ͼ90% of the total PMCA protein (241) . Sperms of PMCA4 null mice were still able to fertilize eggs (264) but were incapable of achieving hyperactivated motility, and thus could not reach them to perform the fertilization. Ultrastructural analyses of the sperm tail failed to reveal abnormalities in the motility apparatus but showed increased condensation of mitochondria, indicating that they had become overloaded with Ca 2ϩ and had thus become dysfunctional. The ablation of the PMCA4 gene produced other localized dysfunctions, for instance, in the modulation of the Ca 2ϩ signals in B-lymphocytes (52) , and in the contractility of vascular smooth muscles (226) . The absence of phasic contractions, however, was due to the large number of smooth muscle cells dying in the isolated tissue, not to the dysfunction of the PMCA4 pump. Interestingly, when PMCA4 knockout mice were backcrossed with the original strain, the smooth muscle phenotype disappeared, to be restored by superimposing a heterozygous PMCA1 null mutation: thus both PMCA1 and PMCA4 pumps appear to be essential for the control of the homeostasis of Ca 2ϩ in vascular smooth muscle cells. Further studies on PMCA4 knockout mice and PMCA1 heterozygous mice (with only one copy of the PMCA1 gene) had shown that these two isoforms may have different roles in the regulation of bladder smooth muscle contractility (186) : the PMCA1 isoform appears to be important for the generalized Ca 2ϩ extrusion function and the PMCA4 isoform for the modulation of acetylcoline receptor signaling. Again, this suggests that the PMCA4 isoform may be a signaling enzyme rather than a housekeeping Ca 2ϩ controlling pump. Important physiological functions of the PMCA4 isoform were also revealed by studies on mice overexpressing it rather than by ablating it. Early studies in which the PMCA4 pump had been expressed specifically in the myocardium of the rat, and in vascular smooth muscle cells in mice, had indicated a role in the modulation of myocardial growth and hypertrophy (118) . They also indicated a role in the regulation of peripheral vascular tone, as the mice displayed increased peripheral blood pressure (111, 265) .
Transgenic mice overexpressing the PMCA4 pump or a COOH-terminally truncated version lacking 120 residues, and thus also the PDZ-binding domain, have extended the work that had shown that the pump interacts with the neuronal nitric oxide synthase (nNOS) via its PDZ domain and inhibits its activity by decreasing local Ca 2ϩ concentration (267) . nNOS is important in heart physiology, as it regulates cardiac contractility (11), Ca 2ϩ cycling (154, 271) , and redox equilibrium (121) and is needed to sustain the ␤-adrenergic response (217) . Overexpression of the full-length pump, but not of the COOH-terminally truncated version, reduced the ␤-adrenergic contractility response. nNOS inhibitors reduced the contractility to the levels observed by overexpressing PMCA4, confirming the role of PMCA4 as a regulator of the activity of nNOS in heart (218). PMCA4, however, also has other roles in cardiac physiology. The ablation of its gene, in addition to the effects described above, affected the process of cardiac hypertrophy. The hypertrophic response to tranversal aortic restriction was abolished in PMCA4 knockout mice. In contrast, the hypertrophic response to physical exercise was preserved. The hypothesis has been put forward that these effects are related to the regulation of the Foxo3a protein degradation pathway by the PMCA4-nNOS complex (218).
Nongenetic alterations of PMCA pumps
Nongenetic alterations of PMCA pumps have also been claimed to contribute to pathological processes (reviewed in Ref. 176) . As a rule, these alterations decrease the content and/or the activity of the pump (however, see below for the case of some cancers), predictably generating situations of cytosolic Ca 2ϩ overload that would disturb normal cell life. In general, these alterations and their effects are less precisely defined, molecularly, than those linked to genetic defects, and it is frequently difficult to decide whether the pump deficiency has a primary causative role in a given disease or is a consequence of it. The problem is exacerbated by the existence of concurrent membrane defects that could in turn affect the function of the PMCAs. However, in a number of pathologies, the dysfunction of the pump appears to be at least one of the causative etiological factors. A selection of the cases that seem to have particular interest will be presented here. It will be necessarily succinct, as the complete coverage of all conditions that have been described would place an unacceptable burden on the space of this contribution. In addition, a large number of the reported findings at the moment are still essentially phenomenological.
PMCA defects have been described in a large number of disease conditions, among them the oxidative stress in several tissues, particularly brain, brain ischemia, diabetes, atherosclerosis, aging, neurodegenerative diseases, and various disturbances of calcium metabolism. Numerous studies have also reported PMCA defects in various cancer types (reviewed in Ref. 206) in line with the accumulating evidence on the involvement of Ca 2ϩ homeostasis dysfunction in the process of malignant transformation. The findings of overexpression of the mRNA of PMCA2 and, albeit to a lower degree, of PMCA4 in some breast cancer lines (173) is thus particularly interesting. A previous study by the same authors had found that the mRNA of PMCA1 was also overexpressed in breast cancer lines. They also found that the antisense-mediated inhibition of PMCA pumps in the tumorigenic breast cancer cell line MCF-7 dynamically inhibited cell proliferation when PMCAs were inhibited to a level that did not completely prevent Ca 2ϩ efflux and did not induce cell death (174) . Similar studies have been performed on intestinal colon cancer cells (12) , showing that the expression of the PMCA4 pump was specifically augmented during the differentiation of the HT-29 cancer line (PMCA1 pump was unaffected), suggesting that less differentiated stages could be associated with compromised Ca 2ϩ efflux. Indeed, the PMCA4 pump transcripts were downregulated in the early progression of some colon cancers (G. Mon-teith and S. J. Roberts-Thomson, personal communication).
The case of cancer cachexia, the tissue wasting that frequently complicates malignancies, is of interest from another angle as well, as it links the PMCA pump defect to the abnormal activation of calpain induced by the specific decline of the natural calpain inhibitor calpastatin. The total level of the PMCA protein was found to be decreased in skeletal muscles in cachexia (58) , and it is of interest that a reduction was also found in the hearts of tumor bearers. The degradation of PMCA pumps by calpain in vivo may be a more general phenomenon in pathology and has indeed been observed in the brain of rats subjected to global brain ischemia followed by 48 h of reperfusion (95, 210) . A decrease of the PMCA pump protein has also been observed in several regions of the brain of gerbils subjected to forebrain ischemia followed by prolonged reperfusion (177, 178) . The study did not establish that the decrease was due to the degradation of the PMCA pumps, but it is interesting that the decrease only concerned PMCA1, the content of which in the forebrain membranes decreased by ϳ40%. Since a study on the purified pump isoforms has established that PMCA1 pump has peculiar calpain sensitivity (114) , it appears very likely that the decrease found in the gerbil forebrain was due to the degradation of PMCA1 by calpain.
A large number of studies have detected damage to the PMCA pumps by reactive oxygen (and nitrogen) species. The case of 4-OH-2,3-trans-nonenal (HNE), an aldehyde product of fatty acid oxidation, deserves to be mentioned. HNE has been found to inhibit the PMCA pump in erythrocytes (244) and is present in oxidized low-density lipoproteins (LDLs), which are found in atherosclerotic lesions. Exposure of platelets to oxidized LDLs (not to native LDLs) inhibited the platelet PMCA pump and massively increased platelet Ca 2ϩ content (329) , suggesting that a pump defect induced by oxidized LDLs could contribute to pathologies like atherosclerosis and hypertension. Reactive nitrogen species (RNS) such as the NO radical and peroxynitrite (ONOO Ϫ ) have also been found to inactivate the pump (277), degrading it when applied to it in the purified state (331) . The ONOO Ϫ -induced degradation pattern of the erythrocyte PMCA has also been observed in newborn asphyxia, a major cause of childhood neurological defects (331) . The brain damage caused by seizures, complex partial seizures, and status epilepticus has also been related to PMCA pump alterations. An interesting study on kainate-induced seizures has revealed a changed expression pattern of the PMCA isoforms (97) . The transcript levels of the PMCA1 and PMCA2 pumps were decreased in the pyramidal cells of the CA1 and CA3 regions of the hippocampus, whereas those of the PMCA3 pump were unchanged. The decrease was found to precede the demise of the neurons. The isoform specificity of the transcript changes emphasizes the differential activity, and thus the differential role, of the PMCA pumps , and underlines the complex interplay of the PMCA pump isoforms in the control of neuronal Ca 2ϩ homeostasis under changing physiological conditions and under the stress of pathology. This point has been repeatedly touched on above, but deserves to be mentioned again.
Diabetes has also seen a large number of contributions on the possible involvement of PMCA pumps. Ca 2ϩ is known to have an important role in the process of pancreatic insulin secretion: glucose induces Ca 2ϩ entry and oscillations in the ␤-cells whose duration depends on its extracellular concentration. ␤-Cells express a unique combination of PMCA pump isoforms (1b, 2b, 3a, 3c, and 4a) (147, 307) , a finding that suggests an important, probably isoform-specific, role of the PMCA pump in the regulation of ␤-cell Ca 2ϩ homeostasis (147, 307) . The PMCA pump is inhibited by glucose, cogently suggesting that its modulation indeed participates in the homeostasis of Ca 2ϩ in ␤-cells (127, 181) . The PMCA pump activity of ␤-cells of non-insulindependent diabetic mellitus rats is lower than in the controls, suggesting that a PMCA-mediated defect in Ca 2ϩ homeostasis may contribute to the diabetic pathology. The PMCA pump activity defect is actually not limited to ␤-cells: erythrocytes of diabetic patients have also been shown to have increased Ca 2ϩ content and decreased PMCA pump activity (104, 105) , although the PMCA pump defect was only detected in patients with diabetic neuropathy (202) . Decreases of PMCA pump activity were also found in renal cortical cells (180) and in brain (228) . Somewhat paradoxically, however, PMCA pump activity was instead found to increase in the sarcolemmal membranes of skeletal muscles of rat in which diabetes was induced by the treatment with streptozotocin (286) .
Finally, defects in the PMCA pump have been described in disease conditions in which the general organismic Ca 2ϩ homeostasis is altered. Considering the essential role of the PMCA pump in the homeostasis of Ca 2ϩ in cells, these defects are not surprising. One could mention the downregulation of the expression of the PMCA2 and PMCA3 pumps in the renal tubules of hypercalciuric rats (44) and the general PMCA pump dysfunction in familial hypercalcemia (72) .
IV. CONCLUDING REMARKS
Ca
2ϩ pumps have been known for more than 40 years as essential actors in the maintenance of the cellular homeostasis of Ca 2ϩ . Of the three pumps that operate in mammalian cells, one (the SPCA pump) has only become known recently, adding new complexity to the already crowded panorama of cellular transporters of Ca 2ϩ . Important distinctive features of the reaction mechanism, of the regulation, and of the specific roles played by the three pumps in the process of Ca 2ϩ homeostasis have gradually become known. The recent solution of the 3D structure of the SERCA pump has greatly advanced knowledge in the area, providing important new information on the catalytic mechanism of the pump and on the path used by Ca 2ϩ to traverse its molecule. In parallel with the spectacular advances in the understanding of the molecular structure of the pumps, the area of pump malfunction has also emerged recently. It has rapidly acquired prominence, in keeping with the growing awareness that one of the distinctive features of the Ca 2ϩ signal is ambivalence. Ca 2ϩ pump dysfunctions are generally not linked to the extreme situations of cell catastrophe induced by the uncontrolled, massive, and protracted Ca 2ϩ overload. They generate instead subtler disease phenotypes that are generally cell specific, and could possibly even only prevail in defined subcellular domains. Table 3 offers a summary of all genetic or related defects of the three pumps that are known today. As the table shows, only a handful of genetic Ca 2ϩ pump diseases have become known in humans, but the larger number of spontaneous and induced conditions which have been detected and studied in model animals have considerably enlarged the spectrum of possible pump dysfunctions. The genetic phenotypes have so far attracted most of the attention, but nongenetic pump alterations are also being increasingly investigated. The topic of Ca 2ϩ pump dysfunction is expanding rapidly and will certainly generate important dividends, including a more complete understanding of the significance of the Ca 2ϩ signaling process in healthy cells.
NOTE ADDED IN PROOF
Very recently a correlation has been found between human systolic blood pressure and the locus of the PMCA1 gene (ATP2B1) on chromosome 12q24 in a vast number of Korean individuals (53a). The authors have noticed the correlation of their findings with the vascular phenotypes (loss of vein contraction) in mice with no copies of the murine gene for PMCA4 (Ref. 226 in text) and have suggested that PMCA1 could function as a modified locus for phasic contraction.
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